Regulation Of Toll-Like Receptor 9 By The Heat Shock Protein Gp96 And Proteolytic Cleavage by Brooks, James
  
 
REGULATION OF TOLL-LIKE RECEPTOR 9 BY THE HEAT SHOCK PROTEIN 
GP96 AND PROTEOLYTIC CLEAVAGE 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
by 
James Christopher Brooks 
May 2012
  
 
 
 
 
 
 
 
 
 
 
 
© 2012 James Christopher Brooks
  
REGULATION OF TOLL-LIKE RECEPTOR 9 BY THE HEAT SHOCK PROTEIN 
GP96 AND PROTEOLYTIC CLEAVAGE 
 
James Christopher Brooks, Ph. D. 
Cornell University 2012 
 
 
Toll-like receptors (TLRs) represent the innate immune system’s first line of defense 
against invading pathogens. TLRs are germline encoded type I transmembrane 
proteins that recognize pathogen associated molecular patterns (PAMPs) which tend to 
define broad classes of pathogens. TLRs exhibit both surface and intracellular 
localization. This global cellular distribution of receptors facilitates detection of 
PAMPs expressed on the surface of foreign organisms or encapsulated within them. In 
the case of nucleic acid-sensing TLRs, this distribution is also a regulatory 
mechanism, protecting the host from harmful response to self-nucleic acids. TLR9 
primarily detects microbial DNA, however, when self-DNA is in complex with 
HMGB1, anti-nuclear antibodies, or an antimicrobial peptide such as LL37, it is 
delivered to TLR9 in endosomes and can elicit inflammatory pathology.  
 
In this dissertation, I investigated the roles that the heat shock protein gp96 and 
proteolytic cleavage play in regulating TLR9 trafficking and signaling. gp96 was 
known to be essential for proper folding of TLRs, including TLR9, in the endoplasmic 
reticulum. However, treatment with a novel gp96 inhibitor, WS13, suppressed CpG 
 DNA induced NF-κB activation, MAP kinase ERK phosphorylation, and TNF-α 
secretion, indicating additional roles for gp96 in TLR9 biology. TLR9 and gp96 were 
found associated in the lysosomes of stably transfected HEK293 cells. Inhibition of 
gp96 caused proteolytic cleaveage of TLR9 to an 80 kD form identical in molecular 
weight to the proposed mature form of this receptor, however, signaling was inhibited 
under these conditions. Furthermore, proteolytic cleavage is not universal among all 
cell types. Induction of proteolytic cleavage in HEK293 cells, which do not normally 
generate the 80 kD mature form of TLR9, inhibited CpG DNA-induced NF-κB 
activation. A retroviral construct analogous to the mature form of TLR9 failed to 
reconstitute CpG DNA induced responses in HEK293, macrophages and dendritic 
cells. This inability to respond to CpG DNA correlates with an inability to traffic 
outside the ER compartment. 
 
In summary, this dissertation explores the regulation of TLR9 signaling by gp96 and 
proteolytic cleavage. Better understanding of the mechanisms which regulate TLR9 
signaling may result in new drug targets for the treatment of autoimmune diseases. 
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CHAPTER 1: 
INTRODUCTION* 
 
* Portions reprinted from Cynthia A. Leifer and James C Brooks “Regulation of Nucleic 
Acid Sensing Toll-like Receptors in Systemic Lupus Erythematosus”, Systemic Lupus 
Erythematosus. Edited by Hani Almoallim. Intech ISBN 978-953-307-868-7. Copyright 
2011.  
 
Innate Immunity 
The mammalian immune system is an amazing product of evolution with the ability to 
theoretically recognize every possible antigen that could be expressed by a pathogen. The 
recombination of genes allows for the generation of T cell receptors or antibodies with a 
multitude of specificities, and this is known as the adaptive immune system.  As with all 
things in life there are consequences, and the major consequence of utilizing a system as 
intricate and precise as the adaptive immune system is the amount of time that is 
necessary to generate a response through it. The response via the adaptive immune 
system upon primary exposure to an antigen reaches its peak at seven to ten days. When 
the generation time of most pathogens can be measured in minutes to hours, the host 
would be overwhelmed by the sheer number of microbes it must control before the 
adaptive immune response could be fully engaged. The solution to this problem is a 
second arm of the immune system termed the innate immune system. The innate immune 
system responds to the threat of a pathogen immediately and serves as a method of 
controlling pathogens until the adaptive immune system is able to sufficiently respond. 
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While the adaptive immune system utilizes B and T cell receptors and antibodies as its 
main methods of pathogen recognition, the innate immune system utilizes pattern 
recognition receptors (PRRs). These PRRs are germline encoded receptors that recognize 
conserved structures that are generally required for survival, termed pathogen associated 
molecular patterns (PAMPs). This germline encoding of receptors utilized by the innate 
immune system is in contrast to the adaptive immune system, which relies on 
recombination of genes to generate specificity. The fact that PAMPs are often critical for 
the survival of the pathogen reduces the likelihood that the pathogen will mutate them in 
order to avoid immune recognition. The cells of the innate immune system respond not 
only via direct killing of pathogens but also by secreting cytokines and chemokines 
important for the activation and recruitment of the cells of the adaptive immune system. 
One such class of PAMPs recognized by the innate immune system is nucleic acids. 
 
Toll-like Receptors 
Toll-like receptors (TLRs) are a family of innate immune receptors that directly detect 
molecular structures and initiate signaling. Engagement of TLRs initiates innate immune 
responses that promote microbial killing and antigen presentation to educate T cells and 
B cells. At least 10 different TLRs recognize various microbial structures such as 
lipopeptides (TLR1, TLR2, and TLR6) (1,2), lipopolysaccharide (TLR4) (3), bacterial 
flagellin (TLR5) (4), double stranded RNA (dsRNA, TLR3) (5), single stranded RNA 
(ssRNA, TLR7, TLR8) (6), and single stranded DNA (ssDNA, TLR9) (7). TLRs are type 
I transmembrane receptors with C-termini facing the cytoplasm of the cell and 
ectodomains either at the cell surface or in the lumen of intracellular compartments. The 
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cytoplasmic domain has homology with the IL-1 and IL-18 receptors and has been called 
the Toll/IL-1-like receptor domain (TIR). The three-dimensional structures of two TLR 
cytoplasmic TIR domains have been solved and are globular with many surfaces for 
protein-protein interactions (8). The TIR domain associates with several adapter proteins 
that initiate signal transduction. These adapters include myeloid differentiation factor 88 
(MyD88), and TIR-domain-containing adapter-inducing interferon-β (TRIF, also known 
as MyD88 adapter-like, MAL), which promote production of proinflammatory cytokines 
and type I interferons. The ectodomain is composed of a series of leucine rich repeats that 
form a curved solenoid (Figure 1.1). Alignment studies predicted a model structure for 
the ectodomains of TLRs (9), which was supported by crystallographic studies (10-15). 
TLRs are expressed on a wide variety of cell types including B cells, T cells, dendritic 
cells, macrophages, and intestinal epithelial cells, although different cell types have 
unique repertoires of TLR expression (16). For example, human plasmacytoid dendritic 
cells express the nucleic acid-sensing TLRs, TLR7 and TLR9. 
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Figure 1.1. Model of TLR9 structure. TLR9 is composed of a lumen-facing ecto-
domain made of 25 leucine-rich repeats (LRR), a transmembrane domain, and a cytosolic 
TIR domain used to bind and transduce signals through adaptor proteins. The ecto-
domain contains two known sites of proteolytic cleavage, one between aa 441 and 470 
and a second between aa 724 and 735 resulting in mature TLR9 and soluble TLR9, 
respectively. 
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Nucleic Acids as PAMPs 
Response to DNA, the response is dependent on a 5’-cytosine-guanosine-3’ dinucleotide 
(CpG). The cytosine must be unmethylated, and is active when surrounded by specific 
bases, which together form the CpG motif (17). These CpG motifs are rare in vertebrate 
DNA due to reduced frequency of the CG dinucleotide (CpG suppression) and increased 
frequency of cytosine methylation (18-20). CpG motifs are present and functional in 
bacterial DNA, in plasmid DNA produced in bacteria, and in synthetic DNA. Variation of 
sequence and physical structure of synthetic DNAs have resulted in characterization of 
least four types of CpG oligodeoxynucleotides each with different activity on cells. Three 
are stimulatory, and one is inhibitory (21-23). Inhibitory DNAs do not require a CpG 
motif and the mechanism of inhibition has not been clearly defined (21,24,25). A recent 
report indicates that these inhibitory DNAs may function through preferentially binding 
to the mature form of TLR9 to inhibit the binding of stimulatory DNA (26). However, it 
seems unlikely that the mechanism can be contributed solely to competition as the 
response of RAW 264.7 macrophages to stimulatory DNA was inhibited by fifty percent 
by a ten-fold lower concentration of inhibitory DNA (27). Type A CpG DNAs (also 
called D) induce robust type I interferon production, while type B CpG DNAs (also 
called K) induce B cell proliferation and proinflammatory cytokine production (22). Type 
C CpG DNAs have properties of both type A and type B CpG DNAs and thus induce 
both types of cellular responses (28).  
 
Regardless of their class, CpG DNAs require endocytosis and acidification of endosomes 
for activity. Blockade of uptake by immobilization of the CpG DNA on beads inhibits the 
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B cell proliferative activity of synthetic CpG DNAs (29). Inhibition of endosomal 
acidification blocks CpG DNA-induced cytokine release by macrophages (30). 
Furthermore, cellular activation by CpG DNA initiates on endosomes (31). Vertebrate 
DNAs are poorly internalized, which contributes to their poor stimulatory activity. 
However, vertebrate DNA is stimulatory when in complex with proteins such as high 
mobility group box 1 (HMGB1), the antimicrobial peptide LL37, or anti-DNA antibodies 
(32-34). Whether the CpG DNA induces proinflammatory cytokines or type I interferon 
also depends on the endosomal compartment where the DNA is retained (35). Honda and 
colleagues demonstrated that different types of DNA are trafficked to and retained within 
different endosomal compartments in plasmacytoid dendritic cells. For example, the type 
I interferon inducing CpG DNAs (type A) rapidly co-localized with FITC-dextran, a 
marker for early endosomes, but failed to co-localize with lysosomal markers (35). In 
contrast, rapid localization with lysosomal markers correlated with proinflammatory 
cytokine production induced by type B CpG DNAs (35). In another study the outcome of 
cellular responses to the DNA types could be swapped by changing the physical and 
chemical properties of the DNA (36). Multimerization of type B CpG DNAs, so that their 
physical structure resembled type A CpG DNAs, caused them to be retained in early 
endosomes and induce A-type responses. Response of B cells was also dependent on 
CpG DNA type and delivery mechanism (37). These studies strongly correlated location 
of DNA detection with cellular outcome and suggested that manipulation of localization 
and receptor recognition could change the outcome of cellular response. 
 
At concentrations of CpG DNA used by many investigators, uptake occurs by fluid phase 
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endocytosis. Uptake of CpG DNA reached a plateau at 2 hours, was slowed at low 
temperature, and was inhibited by known endocytosis inhibitors such as sodium azide 
and cytochalasin B (38). Yet, at lower concentrations, uptake was significantly more 
efficient, which indicated that the CpG DNA was internalized by receptor-mediated 
endocytosis. Using radiolabeled cells, multiple groups demonstrated specific DNA 
binding proteins that likely assisted in internalization and trafficking of CpG DNA to the 
correct endosomal compartment where it encountered TLR9 (38,39). However, the 
identity of these receptors remains unknown. During the internalization process, CpG 
DNA transits though both early and late endosomes, which is important because, as 
mentioned above, CpG DNAs trigger different cellular outcomes depending on the 
compartment where signaling initiates. 
 
Internalization of both CpG and host DNA is facilitated by several host proteins such as 
high mobility group protein 1 (HMGB-1), the antimicrobial peptide LL37, and 
antibodies. The cationic antimicrobial peptide LL37 was highly elevated in the skin of 
patients with psoriasis (33). LL37 formed a stable complex with host DNA, and induced 
a TLR9-dependent, DNase-sensitive, type I interferon response from human 
plasmacytoid dendritic cells. The nuclear factor HMGB1 is retained within cells under 
normal conditions, but cell death and inflammation releases HMGB1, which formed a 
stable complex with host DNA. Association of CpG DNA-A with HMGB1 dramatically 
enhanced production of type I interferon (32). In fact, HMGB1 was found in immune 
complexes with host DNA. Immune complexes from Systemic Lupus Erythematosus 
(SLE) patient serum were enriched in CG content within the DNA, consistent with 
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increased presence of potential stimulatory motifs (40).  
 
Nucleic acid-sensing TLRs detection of self-ligands 
Complexes with DNA bound to anti-idiotype B cell receptors (rheumatoid factor) and to 
Fc receptors to mediate internalization (34,41). Synergistic cytokine production and 
autoantibody induction by enhanced uptake of DNA-containing immune complexes 
likely contributes to the induction and propagation of anti-nucleic acid antibody 
production so frequently observed in SLE. Altogether, these studies demonstrate that 
while host DNA alone is not very immunostimulatory, association with a variety of 
different proteins, present in disease states, promotes endosomal uptake where the DNA 
can associate with TLRs and induce pathologic interferon responses. By either 
mechanism the uptake was very efficient and delivered the complexes to the endosomal 
compartment. 
 
When the stimulatory activity of CpG DNA was first described, it was thought to 
represent microbial DNA and that self-DNA was non-stimulatory. This was due to the 
requirement for the central CG dinucleotide, unmethylation of the C, and the selectivity 
for surrounding bases. These arguments held for many years, however, the mammalian 
genome has the potential to induce TLR9-mediated responses (42,43). Many studies, 
including the ones reviewed below, have been focused on understanding what regulates 
TLR9 mediated responses and why self-DNA is not normally detected. However, recent 
studies suggest that TLR9 signaling is important for normal responses like wound repair 
(44-46). 
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Cells go to great lengths to assure that DNA is not released into the extracellular milieu 
when they die by condensing and digesting their DNA during apoptosis. However, 
necrosis and neutrophil extracellular trap (NET) formation intentionally releases DNA 
that can induce inflammatory responses (47-49). Interestingly, SLE neutrophils were 
primed by high type I interferon levels in vivo, and in response to immune complexes, 
the neutrophils from SLE patients generated NETs that had a high content of DNA, LL37 
and HMGB1. These proteins protected the DNA from degradation and facilitated 
internalization, and thereby increased the inflammatory potential of the host DNA. 
Therefore, since it is purposefully released under certain conditions, there must be other 
regulatory mechanisms to avoid response to host DNA. DNase is present in serum and in 
the extracellular environment and degrades potentially stimulatory host DNA. DNase 
deficient mice were born healthy but develop lupus-like disease at about six months of 
age (50). Heterozygous mice have increased serum concentrations of anti-nuclear 
antibodies, and increased glomerulonephritis. However, in homozygous DNase-deficient 
mice, these SLE parameters were even higher. Mutations in DNase have been identified 
in SLE patients (51), and, together, these studies suggest that DNase is an important 
enzyme to prevent response to host DNA.  
 
Interestingly, recent studies have shown that detection of self-DNA may be a normal 
biological process, and is, in fact, critical for wound healing (45,46). In the absence of 
TLR9, full thickness biopsy wound healing was delayed, and application of CpG DNA, 
in wild-type mice, enhanced healing in a TLR9 dependent manner (45). These data 
suggest that TLR9 plays an important role in wound healing. In a different model, tape 
stripping-induced epidermal injury caused plasmacytoid dendritic cell and neutrophil 
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infiltration (44). This response was accompanied by production of type I interferon, and 
was dependent on the signaling adapter molecule MyD88. Treatment of wild-type mice 
with a TLR7-TLR9 inhibitor reduced the response, implicating these TLRs in the 
process. In lupus-prone mice, the same tape-stripping procedure led to chronic wounds 
with a type I interferon signature that resembled SLE skin lesions. Therefore, detection of 
DNA and RNA by TLR9 and TLR7 is important for normal wound healing. 
Dysregulation of this pathway in SLE likely contributes to autoimmune inflammation, 
especially in the skin, and is a potential target for therapeutic intervention.  
  
Compartmentalization of TLR9 
Infectious agents replicate in various locations outside and inside cells. Bacteria and 
viruses are internalized into endosomes, and some can escape into the cytoplasm. 
Therefore, positioning of TLRs is important for detecting components of microbes in the 
varied locations where they can reside. Some TLRs, such as TLR2, TLR4, and TLR5, are 
expressed at the cell surface to detect ligands expressed on the surface of bacteria 
(lipopolysaccharide, TLR4; lipopeptides, TLR2; and flagellin, TLR5). However, nucleic 
acids, such as DNA and RNA, are encapsulated within bacteria and viruses, and are only 
released upon internalization into endosomes. To accommodate this, nucleic acid sensing 
TLRs are localized intracellularly. For example, TLR9 is primarily found in the 
endoplasmic reticulum (ER) of resting cells (52,53) where it colocalizes with ER, and not 
endosomal, markers. Since detection of DNA occurs in endosomes, these data suggest 
that that there is an induced trafficking event that leads to TLR9 entry into this 
compartment (53). The unique compartmentalization of nucleic acid-sensing TLRs has 
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been proposed as a major regulatory mechanism to prevent response to host DNA (54). 
Fusion of the ectodomain of TLR9 with the transmembrane domain and cytoplasmic tail 
of TLR4 created a protein that localized to the cell surface. This change in localization 
endowed the TLR9 ectodomain with the ability to respond to host DNA (54). These data 
support a model where TLR9 is specifically trafficked intracellularly to avoid access to 
the extracellular milieu, thereby preventing recognition of host DNA. 
   
 
Trafficking of TLR9 through the Golgi to localize in the endolysosomes 
 
While TLR9 predominantly resides in the ER it must traffic to the endosomal 
compartment where it encounters endocytosed CpG DNA (52,53). Normally, 
transmembrane or secreted proteins synthesized in the ER traffic through the Golgi to 
access the cell surface or intracellular endosomes. However, TLR9 was found to be 
sensitive to endoglycosidase H (endo H) treatment, which indicated that TLR9 had not 
reached the Golgi (52). In 2009 Chockalingam et al., showed that Brefeldin A inhibited 
TLR9 response to CpG DNA (55). Since Brefeldin A is a small molecule that inhibits 
transport of proteins from ER to Golgi, TLR9 signaling appeared to be dependent on 
Golgi trafficking.  
  
When proteins traffic through the Golgi, the high mannose glycans are processed to 
hybrid forms that are still cleaved by Endo H; therefore, highly specific lectins were used 
to determine whether TLR9 had glycan modifications indicative of Golgi transit (55). 
Lectins are plant proteins that selectively recognize carbohydrate structures. For example, 
Datura stramonium (DS) lectin specifically recognizes “Galβ1→4GlcNac” structures 
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present only on proteins that have been processed by Golgi resident enzymes. DS lectin 
bound to TLR9, which confirmed that TLR9 trafficked through the Golgi during 
synthesis (55). TLR9 immunoprecipitated from the lysosomal compartment of HEK293 
cells also bound DS lectin, and co-immunoprecipitated with the signaling adapter MyD88 
(55). These data indicated that lysosomal TLR9 had transited through the Golgi and 
contributed to signaling.  
 
Proteins that regulate intracellular localization and trafficking 
Several proteins are critical for TLR9 trafficking both out of the ER and to the endosomal 
compartment (Figure 1.2): UNC93B1, adapter protein 3 (AP3), a protein associated with 
TLR4 (PRAT4A), Slc15a4, and glycoprotein 96 (gp96, also known as glucose regulated 
protein 94 (gp94). Wild-type mice exposed to recessive N-ethyl-N-nitrosourea-induced 
mutagenesis were screened for the ability to respond to TLR ligands and revealed a 
mouse line that lacked response to TLR3, TLR7, and TLR9 ligands. These mice had a 
single point mutation (H412R) in UNC93B1 (56). In dendritic cells from these mice, 
TLR7 and TLR9 did not localize to the endosomal compartment (57). Interestingly, 
UNC93B1 seems to play opposing roles in regulation of TLR7 and TLR9 (58). 
Reconstitution of UNC93B1 deficient cells with UNC93B1 containing a single point 
mutation (D34A) resulted in hyperresponsivenss to TLR7, yet hyporesponsiveness to 
TLR9, ligands. Therefore, the role of UNC93B1 in regulation of nucleic acid sensing 
TLRs is clearly important, and interfering with UNC93B1 function has different effects 
on signaling by different TLRs.  
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Figure 1.2. Regulation of TLR9 trafficking. After synthesis in the ER, TLR9 associates 
with gp96. TLR9 traffics out of the ER to the Golgi in a manner dependent on gp96, 
PRAT4A, and UNC93B1. TLR9 traffics from the Golgi to a sorting vesicle in an AP3 
dependent manner where it is then sorted to the endosomal compartment via a 
cytoplasmic tyrosine motif. In the endosomal compartment TLR9 is proteolytically 
processed either active or negative regulatory forms that modulate TLR9 signaling. 
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Two ER luminal proteins, glycoprotein 96 (gp96) and protein associated with TLR4 
(PRAT4A), are essential for TLR9 exit from the ER. PRAT4A, also known as CNPY3, 
associated with TLR9, which depended on methionine 145 of PRAT4A (59). In the 
absence of PRAT4A, TLR9 did not access endosomes, and PRAT4A deficient cells 
lacked response through all TLRs, except TLR3 (60). The heat shock protein gp96, also 
called glucose-regulated protein 94 (grp94), and endoplasmin or ERP94, is the ER 
paralog of cytoplasmic heat shock protein 90 (Hsp90) (61-63). Similar to what is 
observed for other Hsps, gp96 expression is induced by the accumulation of misfolded 
proteins and it both binds to and hydrolyzes ATP (64,65). gp96 is essential for the proper 
folding of a variety of substrate proteins that include TLRs, integrins and 
immunoglobulins (66-70). Consistent with its role as a housekeeping protein, embryos of 
gp96 deficient mice only survive 5.5 days (71). gp96 directly associated with TLR9 and 
was required for B cell and macrophage response to CpG DNA (72). A pre-B cell line 
with a frame-shift mutation in gp96 was 10,000 times less sensitive to LPS then the non-
mutant line, which was due to a lack of TLR4 on the cell surface (73). This study 
suggested that gp96 regulated trafficking of TLRs. Further studies using a mouse with 
macrophage specific knockout of gp96 showed that gp96 is essential for TLR9 trafficking 
and signaling, and was in fact a chaperone for all TLRs except TLR3 (66,72). In 2011 
Liu et al., demonstrated that gp96 and PRAT4A directly interact to form a multimeric 
complex with TLR9 (67). This TLR9-gp96-PRAT4A multimeric complex was found to 
be essential for proper TLR9 folding and function, as its disruption either by shRNA or 
point mutation resulted in post-translational inactivation of TLR9 (67). Furthermore, co-
  15 
immunoprecipiation studies revealed that the interaction between TLR9 and gp96 was 
dependent on the presence of PRAT4A (67). Taken together, the data presented by Liu et 
al., demonstrated that PRAT4A is a cochaperone of gp96 thus explaining the phenocopy 
of TLR9 defects in both gp96 knockout and PRAT4A null mice (59,67,72,74). 
 
Cytoplasmic proteins are also important for TLR9 trafficking. Plasmacytoid DCs from 
AP3 deficient mice failed to induce a type I interferon response after CpG DNA 
stimulation despite normal IL-12 production (75). AP3 is a cytosolic protein that 
associates with endosomes and sorts transmembrane proteins from the endosomal 
compartment to lysosome-related organelles (76). In the absence of AP3, TLR9 did not 
colocalize with markers for lysosome-related organelles (75). This group suggested that it 
was these lysosome-related organelles that were critical for induction of type I interferons 
(75). However, this conclusion contradicts previously published studies showing that 
initiation of signaling that results in type I interferon production occurs on early 
endosomes (35,36). In a separate study using the same AP3 deficient mice, both 
proinflammatory and type I interferon production were lost (77). Therefore, AP3 is 
important for TLR9-induced cytokine production, but its exact role in TLR9 biology 
remains unclear. 
 
Recent data have shown that TLR9 signaling also depends on Slc15a4, a twelve-spanning 
transmembrane oligopeptide transporter that localizes to the endolysosomal compartment 
(77,78). Cells from Slc15a4 deficient mice lack response to nucleic acid sensing TLRs 
(77). Again, the specific role of Slc15a4 remains unknown, but may involve 
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endolysosomal transport of TLR9 or a TLR9-associated protein required for TLR9 
function. 
 
Specific motifs in TLR9 that regulate localization and trafficking 
 
Localization of TLRs is regulated by sequences in their transmembrane domains and 
cytoplasmic tails. Fusion of N-terminal segments of TLR4 to the transmembrane and 
cytoplasmic tails of various TLRs resulted in distinct localizations of the chimeric 
proteins (79). For example, TLR4 by itself localized to the cell surface, and fusion of 
TLR4’s ectodomain with the transmembrane and cytoplasmic tail of TLR1, TLR2, TLR5, 
or TLR6 resulted in similar localization (79). In contrast, when TLR4 was fused to the 
transmembrane and cytoplasmic tail of any of the nucleic acid-sensing TLRs, the 
resulting chimeric receptor was not detected at the cell surface (79). Further studies using 
different approaches identified different motifs in TLR9 responsible for this localization 
(54,80). TLR9’s ectodomain fused to TLR4’s transmembrane and cytoplasmic domains 
localized to the cell surface (54). Despite being localized to the cell surface the chimera 
retained the ability to respond to CpG DNA, yet was resistant to endosomal acidification 
inhibitors which normally inhibit TLR9 signaling (54,81,82). Interestingly, co-
immunoprecipitation studies using chimeric proteins revealed that TLR9 associates with 
UNC93B1 via the transmembrane domain and this may explain, in part, the requirement 
for this association in TLR9 signaling (83).  
 
In contrast, the Leifer lab in collaboration with the Segal lab identified a specific 
localization motif in the cytoplasmic tail of TLR9 (80). In this study, the ectodomain of 
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the IL-2 receptor alpha chain, which normally localized to cell surface, was fused to the 
transmembrane and cytoplasmic tail of different TLRs (80). A fusion with the TLR4 
transmembrane and cytoplasmic tail localized to the cell surface; however, a fusion with 
the same regions of TLR9 did not express at the cell surface (80). Truncation analysis 
revealed that deletion of all but four amino acids of the cytoplasmic tail generated a 
protein that was robustly expressed at the cell surface, ruling out a contribution of the 
transmembrane domain to intracellular localization. It is unclear why these two studies 
showed opposite requirements for TLR9 transmembrane domain. Regardless, additional 
truncations and mapping identified a 14 amino acid motif that was important for TLR9 
intracellular localization. Follow-up studies showed that mutation of a critical tyrosine 
(888) within this motif abolished proinflammatory cytokine production. Interestingly, this 
mutant maintained normal interferon responses suggesting that this motif is required for 
trafficking TLR9 to the compartment selectively required for induction of 
proinflammatory cytokines (84). It remains to be determined if this motif is necessary for 
association with AP3 or other regulatory proteins. 
 
Proteolytic regulation of TLR9 
 
In addition to trafficking to specific endocytic compartments, several recent studies have 
demonstrated that TLR9 is proteolytically processed in endosomes and that this 
processing regulates TLR9 function (82,85-88). The ectodomain of TLR9 contains 25 
leucine rich repeats. LRR1-14 and LRR15-29 are interrupted by a region predicted to 
have very little secondary structure, often referred to as the hinge (9). The first described 
proteolytic event was mapped to this hinge region through a mass spectrometric approach 
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(87). The form of TLR9 generated encompasses one-half of the ectodomain and all of the 
transmembrane and cytoplasmic tail. This proteolytic event is inhibited by endosomal 
acidification inhibitors and by broad-spectrum cathepsin inhibitors (86,87). Additional 
studies with specific cathepsin inhibitors, and in cathepsin deficient mice, did not reveal a 
unique cathepsin responsible for the cleavage. This proteolytically cleaved form of TLR9 
was reported to be the mature, active form of TLR9 responsible for recognition of CpG 
DNA (86,87). It was demonstrated that this mature form of TLR9 was able to bind CpG 
DNA (26,86,87). Furthermore, a retroviral construct encoding the mature form of TLR9 
was sufficient to reconstitute CpG DNA induced TNF-α production in TLR9-/- bone 
marrow derived dendritic cells (87). An independent study, showed an additional 
proteolytic event (88). While this study did not reveal the precise location of the 
proteolysis, a specific enzyme, asparagine endopeptidase was shown to be important for 
this cleavage. A more recent study suggested that stepwise processing of TLR9 is 
required to attain fully functional proteolytically processed TLR9 (82). Interestingly, 
knockdown of either PRAT4A (CNPY3) or gp96 by shRNA targeting resulted in a loss 
of proteolytic processing of TLR9, and suggested that these chaperones are required for 
TLR9 to access endosomes (67). The Leifer lab recently showed that TLR9 is also 
proteolytically processed at a completely different position to generate a negative 
regulator of TLR9 signaling (85). This proteolytic event resulted in generation of an 
intact ectodomain separated from the transmembrane domain and cytoplasmic tail. This 
soluble form of TLR9 bound to CpG DNA, associated with full length TLR9, and 
inhibited responses by the full-length receptor in a dominant negative manner (85). In 
contrast to the proteolytic cleavage events which generate mature TLR9, we showed that 
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generation of soluble TLR9 occurred in cells expressing endogenous TLR9 (85). Soluble 
TLR9 is likely important in regulating TLR9 responses since intestinal epithelial cells 
poorly responded to CpG DNA and abundantly generate soluble TLR9 (85) (Figure 1.3). 
Therefore, correlative studies on TLR9 in different pathological conditions must account 
for the complexity of TLR9 post-translational modification. 
 
Brief Outline of Dissertation Research 
The global cellular distribution of TLRs facilitates detection of molecular structures 
expressed on the surface of foreign organisms or encapsulated within them (16), and in 
the case of nucleic acid-sensing TLRs, this distribution is also a regulatory mechanism, 
protecting the host from harmful response to self-nucleic acids such as DNA (54). 
However, when self-DNA is in complex with HMGB1, anti-nuclear antibodies, or an 
antimicrobial peptide such as LL37, it is delivered to TLR9 in endosomes and can elicit 
inflammatory pathology (32-34,89-92).  
 
Based on the studies discussed above, we hypothesized that both the ER resident heat 
shock protein gp96 and proteolytic cleavage play critical roles in regulating the response 
of TLR9 to CpG DNA. In the first half of Chapter 3 I describe data showing that gp96 
regulates TLR9 stability and conformation. My results show that gp96 remains associated 
with TLR9 and both proteins traffic to the lysosomal compartment. Pharmacologic 
interference with the gp96-TLR9 interaction inhibits the response to CpG DNA. This loss 
in CpG DNA induced signaling is due to the increased proteolytic sensitivity of TLR9 in 
the absence of gp96, and suggests that TLR9 conformation is gp96 dependent.  
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Figure 1.3. Proteolytic cleavage of TLR9. TLR9 undergoes proteolytic processing in 
two locations in the ectodomain. One cleavage event occurs in the hinge region and is 
mediated by both cathepsins and AEP; it results in the generation of the proposed active 
form, mature TLR9, and a remaining N-terminal fragment. An independent cleavage 
event occurs much closer to the transmembrane domain and generates a soluble negative 
regulatory form of TLR9 (sTLR9) and a C-terminal fragment.  
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In the second half of Chapter 3 I describe data which show that proteolytic cleavage of 
TLR9 is not necessary or sufficient to support CpG DNA induced signaling events. I 
provide evidence that generation of the mature form of TLR9 does not directly correlate 
with response to CpG DNA. A retroviral construct corresponding to the mature form of 
TLR9 (mTLR9471-1032-HA) fails to exit the ER, serves as a dominant negative to TLR9 
signaling, and fails to reconstitute CpG DNA response in any cell type tested. In Chapter 
4 I summarize the data and propose a new model for TLR9 signaling in which gp96 
interaction with TLR9 is not solely critical in the ER but is essential for protecting TLR9 
from proteolytic cleavage after it traffics outside the ER compartment. Furthermore, 
proteolytic processing of TLR9 is neither necessary nor sufficient to reconstitute CpG 
DNA induced signaling in any cell type tested, challenging the current model of obligate 
proteolytic processing of TLR9 in order to respond to CpG DNA.. These results provide 
evidence for therapeutically targeting gp96 as a treatment to suppress diseases in which 
TLR9 signaling plays a role, such as SLE, psoriasis, or rheumatoid arthritis.  
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CHAPTER 2: 
MATERIALS AND METHODS 
 
Reagents and plasmids 
The following antibodies and reagents were used: anti-HA for immunoprecipitation 
(ABM, Richmond, BC, Canada), anti-HA for immunoblotting and anti-HA conjugated to 
fluorescein isothiocyanate (FITC) (anti-HA FITC) for flow cytometry (Roche Applied 
Science, Indianapolis, IN, USA), anti-GFP (recognizes YFP) for immunoprecipitation 
(Invitrogen/Molecular Probes, Carlsbad, CA, USA), anti-GFP for immunoblotting and 
anti-TNF-α conjugated to allophycocyanin (APC) (anti-TNF-α APC) for flow cytometry 
(BD Clontech, Mountain View, CA, USA), anti-LAMP-1, anti-Rab 5 and anti-Calnexin 
(BD-transduction laboratories, San Jose, CA, USA), anti-human gp96 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), anti-phosphorylated and total ERK and p38 (Cell 
Signaling Technology, Danvers, MA, USA), HRP conjugated anti-mouse, rat and rabbit 
secondary (Southern Biotech, Birmingham, AL, USA), HRP conjugated anti-goat 
secondary (Jackson ImmunoResearch Labs, Inc, West Grove, PA, USA), anti-tubulin 
(eBioscience, San Diego, CA, USA), brefeldin A (eBioscience, San Diego, CA, USA), 
geldanamycin (Sigma-Aldrich, St. Louis, MO, USA), poly I:C (Calbiochem, San Diego, 
CA, USA), CpG DNA 10104 5'-TCGTCGTTTCGTCGTTTTGTCGTT-3' and 2006 
3′biotin: 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3’ (Eurofins MWG Operon, 
Huntsville, AL, USA), mouse GM-CSF (Peprotech, Rocky Hill, NJ, USA) All plasmids 
were prepared using Endo free plasmid maxiprep kits (Qiagen Sciences, MD, USA). 
WS13, a gp96-specific Hsp90 inhibitor of the purine-scaffold class (93), was synthesized 
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as previously described (94,95).   
 
Cell culture 
Human Embryonic Kidney (HEK) 293 cells (ATCC #CRL-1573), HeLa (ATCC #CCL-
2), RAW 264.7 cells (ATCC #TIB-71), and ØNX-Ampho cells (Orbigen, San Diego, CA, 
RVC-10001) were cultured in Dulbecco's modified Eagle's medium (DMEM) with 2 mM 
L-glutamine, 50 U ml-1 penicillin, 50 µg ml-1 streptomycin, 10 mM HEPES, 1 mM 
sodium pyruvate and 10% low endotoxin FBS. TLR9-/- macrophage cells (NIH 
Biodefense and Emerging Infections Research Resources Repository #NR-9569) were 
cultured in Dulbecco's modified Eagle's medium (DMEM) with 2 mM L-glutamine, 
10 µg ml-1 ciprofloxacin HCl, 10 mM HEPES, 1 mM sodium pyruvate and 10% low 
endotoxin FBS. 70Z/3 B cells were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium with 2 mM L-glutamine, 50 U ml-1 penicillin, 50 µg ml-1 streptomycin, 
10 mM HEPES, 1 mM sodium pyruvate, 2.5% low endotoxin FBS and 50 µM 
mercaptoethanol. Cells routinely tested negative for mycoplasma. 
 
DNA cloning 
mTLR9471-1032-HA was generated by PCR sewing using mTLR9-HA and the mouse IgκB 
leader sequence from pDisplay (Invitrogen) with the primers as shown in Table 2.1. A 
500 base pair (bp) sequence containing the mouse IgκB leader sequence from pDisplay 
and 5’ sequence from mTLR9, along with a 1700 bp sequence encoding 3’ sequence 
from the mouse IgκB leader, amino acids 471-1032 of mTLR9, 3 C-terminal HA tags 
from mTLR9-HA with an added 5’ XhoI site were cloned via PCR. A second PCR 
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reaction using these two products as templates was performed to “sew” the mouse IgκB 
leader sequence to the mTLR9 sequence. This second PCR product was digested with 
EcoRI, which was encoded in the PCR product containing the mouse IgκB leader 
sequence, and XhoI, then ligated into pcDNA3.1+ or the retroviral vector pBMN-i-GFP 
and verified by sequencing (Figure 2.1). mTLR9441-1032-HA was generated by the same 
method using the primers as shown in Table 2.1.  
 
HEK293 luciferase reporter assay  
The luciferase reporter assay was performed as previously described (55). Briefly, 
HEK293 cells were transiently transfected using TransIT (Mirus, Madison, WI) with 
mTLR9-HA, TLR3,  mTLR9471-1032-HA, or mTLR9441-1032-HA, 5x-NF-κB luciferase 
reporter and empty vector totaling 200 ng/ well of DNA for each well of a 96 well plate. 
Cells were pretreated for one hour with the indicated concentration of inhibitor or left 
untreated prior to overnight stimulation with either 1 µM CpG DNA, 5 µg/ml poly I:C or 
100 ng/ml LPS. Cells were lysed in Reporter Lysis Buffer (Promega, Madison, WI) and 
assayed using a Veritas luminometer using luciferase substrate (20 mM tricine, 2.67 mM 
MgSO4·7 H2O, 33.3 mM DTT, 100 µM EDTA, 530 µM ATP, 270 µM Acetyl CoA, 132 
µg/ml luciferin, 5 mM NaOH, 265 µM magnesium carbonate hydroxide).  
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Table 2.1. PCR primers used in the generation of mTLR9471-1032-HA and mTLR9441-
1032-HA via PCR stitching  
 
Construct Forward Reverse 
GGCCCGCCTGGCATTATGCCCAG 
CAGGTCCATGGTGAACTTGAA
GTTCTTACAGTCACCAGTGGA
ACCTGGAACCCAGAGCAGCAG 
mTLR9471-1032-
HA 
CTGCTGCTCTGGGTTCCAGGTTCC
ACTGGTGACTGTAAGAACTTCAA
GTTCACCATGGAGCTG 
TATCTCGAGCTAAGCGTAGTC
TGGGACGTCGTATGGG 
   
GGCCCGCCTGGCATTATGCCCAG 
CAACAGCTCCTCCTGCTCTGC
ATCATCTGCGTCACCAGTGGA
ACCTGGAACCCAGAGCAGCAG 
mTLR9441-1032-
HA 
CTGCTGCTCTGGGTTCCAGGTTCC
ACTGGTGACGCAGATGATGCAGA
GCAGGAGGAGCTGTTG 
TATCTCGAGCTAAGCGTAGTC
TGGGACGTCGTATGGG 
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Figure 2.1. Diagram of PCR Sewing Technique. Two initial PCR reactions are 
performed, the PCR primers at the region to be joined, or “sewn”, contains nucleotide 
sequence from the other product. A third reaction is performed using the products from 
the initial two reactions as templates the PCR primers corresponding to the region to be 
sewn are removed from the reaction. The overlapping regions will anneal resulting in one 
product where the two initial products are “sewn” together.  
 
pDisplay
mTLR9-HA
mIgkB leader
mTLR9471-1032-HA
mTLR9471-1032-HA
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Retroviral Transduction 
Retroviral supernatants were generated by transfecting the ØNX-Ampho cell line with 
plasmids encoding either mouse TLR9 tagged with hemaglutinin (mTLR9-HA), 
mTLR9471-1032-HA, mTLR9441-1032-HA or empty vector using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). Retrovirus containing supernatants were harvested 27 
and 48 hours later, mixed with 8 μg/mL (final concentration) polybrene (Sigma) and 
added to RAW 264.7 or TLR9-/- macrophage cells. Following centrifugation at 1811 X g, 
32 °C for 90 minutes, the media was changed and cells were incubated for 48 hours at 37 
°C. 
 
Organelle fractionation 
HEK293 cells stably expressing human TLR9 tagged at the N-terminus with 
hemaglutinin (HA-hTLR9) (55) were incubated in homogenization buffer (HB: 0.25 M 
sucrose, 1 mM EDTA, 10 mM Tris, pH 7.4, and protease inhibitor cocktail) on ice for 15 
min and homogenized for 20 strokes with a loose fitting 2 ml glass dounce homogenizer, 
and passed 10 times through a 25G needle attached to a 3 cc syringe. The homogenate 
was centrifuged at 900 x g for 10 min at 4 °C and the postnuclear supernatant was 
transferred to a fresh tube. The pellet was washed with HB, spun at 4 °C and the 
combined postnuclear supernatant was centrifuged one additional time at 4 °C. The 
combined postnuclear supernatant was layered on Percoll in HB (density 1.05 g ml-1) and 
centrifuged for 60 min at 34 000 x g in a 50Ti rotor using a Beckman L-8M 
ultracentrifuge. Fractions (500 µl each) were collected from the top using an AutoDensi-
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Flow IIC gradient unloader (Haake Buchler (Labconoco), Kansas City, MO, USA). 
Refractive index and protein concentration were tested for each fraction to confirm 
separation using a Mark II Refractometer (Reichert Scientific Instruments) and the DC-
BioRad assay, respectively. Laemmli reduced sample buffer (final concentrations 62.5 
mM Tris pH 6.8, 12.5% glycerol, 1% SDS, 0.005% bromophenol blue, 1.7% β-
mercaptoethanol)  was added to each fraction which were then boiled at 95°C for 5 min 
and proteins were resolved by SDS-PAGE. After transfer (15V, 35 min in a Trans-Blot 
SD semi-dry transfer cell (Bio-Rad)), nitrocellulose membranes were immunoblotted for 
the indicated proteins. 
 
3’ biotinylated CpG DNA pulldown 
HEK293 cells or HEK293 cells stably expressing hTLR9-YFP (85) were lysed in sample 
buffer for whole cell lysate control, or lysis buffer and lysates were incubated with 5 µM 
3’ biotinylated CpG 2006 for one hour at 4°C, followed by affinity purification using 
streptavidin coated beads (Pierce) for an additional one hour at 4°C. Purified proteins 
were resolved by SDS-PAGE and transferred to nitrocellulose membranes as described. 
Membranes were immunoblotted for GFP and gp96.  
 
Co-immunoprecipitation 
HEK293 cells transfected with hTLR9-YFP, mTLR9-HA, mTLR9-GFP, mTLR9471-1032-
HA, mTLR9441-1032-HA or empty vector were pretreated as described in the figures then 
lysed (Lysis buffer: 137 mM NaCl, 20 mM Tris pH 7.4, 1 mM ethylenediaminetetraacetic 
acid (EDTA), 0.5% Triton X-100, protease inhibitor cocktail (Roche) and 100 
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µM phenylmethylsulfonyl fluoride) and incubated with anti-TLR9 overnight or anti-HA 
or anti-GFP for two hours before adding protein A/G sepharose beads and incubating for 
an additional one hour. After washing three times in lysis buffer, Laemmli reduced 
sample buffer was added, and samples were boiled. Proteins were resolved by SDS-
PAGE and transferred to nitrocellulose membranes. Membranes were immunoblotted as 
described in the figures. Some membranes were stripped (Restore, Pierce, Rockford, IL) 
and re-immunoblotted. 
 
Cytokine ELISA 
TNF-α production was determined using the mouse TNF-α ELISA MAX Set 
(BioLegend, San Diego, CA, USA) from supernatants of cells pretreated or not with 
inhibitors for 2.5 hours then stimulated for 24 hours. 
 
In vitro proteolysis assay 
RAW 264.7 cells retrovirally transduced with mTLR9-HA were pretreated with either 2 
µM geldanamycin or vehicle control for 2.5 hours. Cells were then lysed in Lysis buffer 
and incubated at 4 or 24°C for the indicated times. Reactions were terminated with the 
addition of sample buffer and samples were boiled. Proteins were resolved by SDS-
PAGE, transfered to nitrocellulose, and immunoblotted for HA and tubulin.  
 
Densitometric analysis  
Quantification of protein bands from radiographic films was performed using ImageJ. 
The lanes of the Western blot are designated using the rectangular selection tool and a 
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profile plot is generated with the size of the peaks corresponding to the intensity of the 
bands in the lane. The base of the peak is then closed off using the straight line tool in 
order to eliminate the background in the Western blot. Peaks of interest are designated 
using the wand tool and ImageJ will label each peak with its size, expressed as both the 
area of the peak itself along with a percentage of the total size of all of the highlighted 
peaks. Data are then imported into GraphPad Prism for graphing (percentage of total) or 
additional analysis (calculating RD). Relative densities (RD) are calculated by dividing 
the areas obtained for different markers as specified in the figures.  
 
Generation of TLR9-/- bone marrow derived macrophage (BMM) 
Bone marrow cells were flushed from the femur of a TLR9-/- mouse and cultured in 
BMM media for five days (DMEM supplemented with 2 mM L-glutamine, 50 U ml-1 
penicillin, 50 µg ml-1 streptomycin, 10% supernatant from L929 cells,  and 10% low 
endotoxin FBS). On days one and three, 1 mL of media was removed and replaced with 1 
mL retrovirus-containing supernatants mixed with 8 μg/mL (final concentration) 
polybrene (Sigma) were added to the cells followed by centrifugation at 1811 X g, 32 °C 
for 90 minutes. Post centrifugation, 1 mL of the media was removed and replaced with 1 
mL fresh BMM media. Differentiation was confirmed by staining the cells with anti-
F4/80 phycoerythrin (PE) antibody (Figure 3.15). Fluorescence was measured on a FACS 
CantoII flow cytometer (BD Biosciences) and analyzed using FlowJo (Tree Star). 
 
 
Generation of TLR9-/- bone marrow derived dendritic cells (BMDC) 
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Bone marrow cells were flushed from the femur of a TLR9-/- mouse and cultured in low 
2-mercaptoethanol (β-Me) BMDC media for two days RPMI supplemented with 2 mM 
L-glutamine, 50 U ml-1 penicillin, 50 µg ml-1 streptomycin, 10% low endotoxin FBS, 
20ng/ml GM-CSF and 50 nM β-Me). On days two and four, 1 mL of media was removed 
and replaced with 1.5 mL retrovirus-containing supernatants mixed with 8 μg/ml (final 
concentration) polybrene (Sigma) were added to the cells followed by centrifugation at 
1811 X g, 32 °C for 90 minutes. Post centrifugation 1.5 mL of the media was removed 
and replaced with 1 mL fresh high β-Me BMDC media (same as low BMDC media 
except with 50 µM β-Me). On day six, 1 mL of the media was removed and replaced with 
1 mL fresh high β-Me BMDC media. Cells were used on day 7. Differentiation was 
confirmed by staining the cells with anti-CD11c PE antibody (Figure 3.15). Fluorescence 
was measured on a FACS CantoII flow cytometer and analyzed using FlowJo. 
 
 
TLR9 deglycosylation 
The TLR9 deglycosylation assay was performed as previously described (55). Lysates 
from TLR9-/- macrophages or wild-type and gp96 mutant 70Z/3 mouse B cells 
retrovirally transduced with mTLR9-HA, mTLR9471-1032-HA, or mTLR9441-1032-HA were 
divided into three equal portions and were either untreated or treated with endo H or 
PNGase F according to the manufacturer's instructions (New England Biolabs) overnight 
at 37°C and the reactions were stopped by adding 6× SDS-PAGE reduced sample buffer 
and boiling at 95°C for 5 min. The samples were analyzed by immunoblotting for HA. 
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Intracellular TNF-α Assay 
TLR9-/- macrophage, BMM, or BMDC were retrovirally transduced with constructs 
encoding mTLR9-HA or mTLR9471-1032-HA. Cells were then stimulated with 5µM CpG 
10104 for 6 hours with the addition of 10µg/mL BFA for the last 4 hours. Cells were 
fixed with 3% PFA for 15 minutes on ice, then stained with anti-HA FITC and anti-TNF-
α APC in 0.1% saponin in PBS with 10% mouse serum for 1 hour on ice. Fluorescence 
intensity was measured with a FACS CantoII flow cytometer. Data were collected with 
FACSDiva (BD Biosciences) and analyzed with FlowJo. 
 
70Z/3 NF-κB response assay 
Wild-type or gp96 mutant 70Z/3 mouse B cell lines were pretreated for one hour as 
described in the figures prior to stimulation for 24 hours.  GFP expression was measured 
by flow cytometry using a FACSCalibur cytometer (BD Biosciences) and data analyzed 
using FlowJo software (Tree Star, Inc). 
 
Lectin blotting 
Lysates from wild type or gp96 mutant 70Z/3 mouse B cells retrovirally transduced with 
mTLR9-HA were immunoprecipitated for HA. Immunoprecipitates were washed with 
lysis buffer, boiled in sample buffer, and resolved by SDS-PAGE. Following transfer to 
nitrocellulose, membranes were blocked using 5x Detector Block (KPL) and incubated 
for 40 minutes with 1.5 µg/mL biotinylated DS lectin (Vector Laboratories, Inc). After 3 
washes of 30 minutes each in Tris-buffered saline with 0.1% Tween 20 (TBST), 
membranes were incubated with avidin-HRP (eBioscience) for 30 minutes. Membranes 
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were washed an additional 3 times for 60 minutes each with TBST before developing 
with SuperSignal West Pico substrate (Pierce).   
 
Statistical Analysis  
Results are expressed as mean and standard deviation. Student’s two-tailed t test was 
used for comparing drug treatments.  
 
SDS-PAGE 
Lysates or immunoprecipitates prepared in SDS -PAGE reduced sample buffer are boiled 
at 95°C for 5 min and loaded into 8 or 10% polyacrylamide gels and electrophoresed in a 
Mini PROTEAN 3 Cell (Bio-Rad) filled with Running Buffer (25 mM Tris, 192 mM 
glycine, 0.1%  SDS) at 150V for 1-1.5 hours. 
 
Semi-Dry Transfer 
After the SDS-PAGE, Whatman paper, nitrocellulose membrane (GE Healthcare) and 
polyacrylamide gel are soaked in Transfer buffer (25 mM Tris, 40 mM glycine, 20% 
methanol) then assembled on a Trans-blot SD semi-dry transfer cell (Bio-Rad) in a stack 
with Whatman paper on bottom, then the nitrocellulose membrane, polyacrylamide gel 
and more Whatman paper on top. The transfer cell is closed and the transfer is run at 15V 
for 35 minutes. 
 
Immunoblotting 
After transfer nitrocellulose membranes are blocked in either 4% milk in 1x PBS + 0.1% 
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Tween-20 (PBS-T, anti-HA, anti-GFP), 5% milk in 1x TBS + 0.1% Tween-20 (TBS-T, 
MAP kinase antibodies), or Detector Block (anti-gp96) for 1 hour. Membranes are then 
incubated with primary antibody for 2hr (PBS-T + 1:20 block, anti-HA and anti-GFP) or 
overnight (5% bovine serum albumin in TBS-T, MAP kinase antibodies or Detector 
Block, anti-gp96). Membranes are washed 3x in TBS-T or PBS-T and incubated with 
secondary antibody for 1 hour washed an addition 3x, developed with chemiluminescent 
substrate and visualized on x-ray film.  
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CHAPTER 3: 
RESULTS 
 
TLRs are responsible for recognizing PAMPs and initiating immune responses. TLR9 is 
responsible for recognizing CpG DNA (7,96). Regulation of TLR9 is critical as there is 
little difference between microbial DNA and host DNA. A portion of this regulation 
occurs at the level of the DNA itself with the frequency of CG dinucleotide repeats being 
suppressed in the mammalian genome (CpG suppression) and most of those present being 
cytosine methylated (18-20). However, a large portion of the regulation occurs at the 
level of the TLR9 protein itself through mechanisms such as localization/trafficking, 
associating proteins, and proteolytic cleavage (54,60,72,73,82,83,86-88). When TLR9 
regulation is subverted, the result is often autoimmune disease or inflammatory 
pathologies (32-34,89-92). Based on the studies cited above I hypothesized that TLR9 
association with gp96 is critical to maintain TLR9 conformational stability and prevent 
proteolytic degradation. Furthermore, I hypothesized that proteolytic cleavage of TLR9 is 
not sufficient for response to CpG DNA. Instead, proteolytic cleavage may be a 
mechanism primarily used by highly phagocytic cells, like macrophages, to degrade 
TLR9 and prevent recognition of self DNA from apoptotic cells. 
 
One ER protein responsible for regulating TLR9 access to endosomes is gp96 
(66,67,72,73). This Hsp regulates intracellular trafficking of both integrins and TLRs 
(66). Although deficiency in gp96 is embryonic lethal, a mouse pre-B cell line with 
functionally defective gp96 fails to respond to ligands for TLR1, TLR2 and TLR4 
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(72,73). Furthermore, macrophage-specific knockout of gp96 abolishes signaling through 
TLR2, TLR4, TLR5, TLR7 and TLR9 (72). These studies demonstrate the critical 
function of gp96 in TLR signaling. However, Hsp function is not restricted to trafficking, 
and it is well established for other Hsps, such as the cytosolic Hsp90, that they may also 
regulate conformation and ligand binding ability of their client proteins through 
continuous association (97-99). For gp96, most studies have been conducted using 
mutant cell lines and gene-deficient mice. By design, these studies were limited to 
determining phenotype in the absence of functional gp96, and thus they may fail to detect 
additional chaperoning functions of gp96. Therefore, we hypothesized that gp96 was 
additionally required to regulate TLR9 conformation, and thus functional activity. 
 
Disruption of the gp96-TLR9 interaction inhibits the TLR9 response to CpG DNA 
The heat shock protein gp96 is required for the TLR9 response to CpG DNA (67,72,73). 
However, in the absence of gp96, TLR9 never gains access to the endosomal 
compartment as demonstrated by a lack of the 80 kilodalton (kDa) mature form (67). To 
circumvent this limitation, we asked whether gp96 regulates TLR9 stability and 
conformation in endosomes using geldanamycin, a benzoquinone ansamycin antibiotic 
that binds with high affinity to the ATP binding pocket of Hsp90 family members, 
including gp96. HEK293 cells were transfected with TLR9 and treated with 
geldanamycin prior to stimulation with the TLR9 ligand CpG DNA. CpG DNA 
stimulation induced NF-κB activation, and geldanamycin inhibited this response (Figure 
3.1A). However, geldanamycin also inhibited background NF-κB activation (Figure 
3.1A).  
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Figure 3.1 (previous page). Inhibition of gp96 reduces CpG DNA-induced responses. 
(A, B) HEK293 cells were transfected with an NF-kB-luciferase reporter, TLR9, and 
TLR3. Cells were pretreated with the indicated concentrations of geldanamycin (GA), 
WS13, or vehicle control (DMSO) prior to stimulation overnight with (A) 1 µM CpG 
DNA, or (B) 5 µg/ml poly I:C. Average luciferase activity (n=3) and standard deviation 
were determined. *P<0.001. Representative of two independent experiments. (C) RAW 
264.7 cells were pretreated for 2.5 hours with the indicated concentrations inhibitor or 
DMSO control and stimulated with 0.5 µM CpG DNA for 30 min. Whole cell lysates 
were assayed for phosphorylated (pERK) and total ERK by immunoblotting. The two 
bands detected by the anti-phosphorylated ERK antibody represent ERK 1 (upper band) 
and ERK 2 (lower band). Representative of three independent experiments (D) RAW 
264.7 cells were pretreated with the indicated inhibitors for 2.5 hours and stimulated with 
5 µg/ml poly I:C for 24 hours. Secreted TNF-α was determined by ELISA. (E, F) As in 
(C) except cells were stimulated with (E) 500 pg/mL LPS or (F) 5 µg/ml poly I:C for 30 
min. (G) As in (D) except cells were stimulated with 0.5 µM CpG DNA for 24 hrs. 
*P<0.005. Representative of two independent experiments. 
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This was likely due to inhibition of cytosolic Hsp90, which was required for many 
signaling pathways including ERK (100) (Figure 3.1C). In contrast to geldanamycin that  
binds with similar affinity to both Hsp90 and gp96 (EC50Hsp90 = 0.03 µM and 
EC50gp96=0.026 µM), WS13 is selective for gp96 (EC50Hsp90 = 33 µM and EC50gp96=0.16 
µM) when tested in an in vitro binding assay against the recombinant proteins (G. 
Chiosis, personal communication). WS13 also inhibited CpG DNA-induced NF-κB 
activation at doses based on the Inhibitory Concentration 50 (IC50) of the drug as 
published by Moulick et al (Figure 3.1A) (101). Importantly, the TLR3 response to poly 
I:C, which was independent of gp96 (67,72), was not inhibited significantly by WS13, 
but was significantly inhibited by geldanamycin pretreatment (Figure 3.1B). Since these 
are membrane permeable drugs, both GA and WS13 will access all gp96 regardless of 
localization and thus all TLR9 that is bound to gp96.  We are measuring the effect of 
these drugs on TLR9 signaling, and TLR9 signaling initiates from endolysosomes 
(52,53,55). Therefore, the inhibition that we observe is most likely on TLR9 in the 
endolysosomal compartment. These studies provide evidence for a specific role for gp96 
in TLR9 signaling. 
 
We next asked whether gp96-specific inhibitors blocked endogenous TLR9 responses to 
CpG DNA. In macrophages, WS13 reduced both CpG DNA-induced ERK 
phosphorylation (Figure 3.1C) and TNF-α secretion (p<0.005, Figure 3.1G) in a 
concentration dependent manner. However, inhibition of gp96 did not significantly 
reduce poly I:C-induced (Figure 3.1D and 3.1F) or LPS induced responses (Figure 3.1E 
and Figure 3.2).  
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Figure 3.2. LPS induced TNF-α secretion is unaffected by WS13 pretreatment. 
RAW 264.7 cells were left untreated or pretreated for 2.5 hours with 2 µM WS13 and 
stimulated with 100 ng/mL LPS for 24 hrs. Secreted TNF-α was determined by ELISA. 
Representative of three independent experiments. 
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Importantly, treatment with the DMSO vehicle did not inhibit CpG DNA-, poly I:C-, or 
LPS induced NF-κB activation, ERK phosphorylation or TNF-α secretion, indicating that 
any inhibition observed when using WS13 was from the drug itself and not the DMSO 
vehicle (Figure 3.1), but the pan-Hsp90 inhibitor geldanamycin blocked all ERK activity 
(Figure 3.1C). Together, these results indicate that gp96 function is required for TLR9-
dependent responses to CpG DNA. It is not surprising that the LPS induced TLR4 
response is unaffected by the gp96 specific inhibitor WS13. Published data using a pre-B 
cell line with a mutant gp96 show that TLR4 is not present on the cell surface and thus 
not able to respond to LPS (73). However, if these same cells were retrovirally 
transduced with a constitutively active TLR4 chimera, NF-κB was still activated 
indicating that in the absence of functional gp96 TLR4 was still folded correctly and its 
signaling pathway was intact (73). Thus the role of gp96 in TLR4 signaling is to 
chaperone TLR4 to the cell surface (73). Since our cells have functional gp96, TLR4 will 
already be expressed on the cell surface before WS13 is administered, and gp96 will no 
longer be required, so it is expected that signaling will not be affected (Figure 3.1E and 
3.2). Thus, unlike TLR4 signaling, gp96 must have additional functions in TLR9 
responses although the Leifer lab has shown that TLR9 can be constitutively found 
outside the ER (55), its response is still inhibited by treatment with WS13 (Figure 3.1A, 
C, and G). 
 
gp96 is associated with TLR9 after exit from the ER  
We next asked whether gp96 association with TLR9 is transient or stable. In 2004 Leifer 
et al. utilized 35S-methionine to label TLR9 transfected into HeLa cells and was able to 
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demonstrate that TLR9 protein was reduced by half at 8 hours post labeling (53). This 
data indicated that eight hours was the half-life of TLR9 protein so we followed TLR9-
gp96 association over a similar time course. HEK293 cells stably expressing N-
terminally hemaglutinin-tagged human TLR9 (HA-hTLR9) were treated with 
cycloheximide for various times, and the interaction between TLR9 and gp96 was 
monitored by co-immunoprecipitation. Cycloheximide binds to the 60S ribosome and 
stalls translation of protein at the second codon by inhibiting tRNA binding, effectively 
stopping all protein translation (102,103). Using cycloheximide allowed us to examine 
one pool of TLR9 throughout the course of the experiment. In our hands the relative 
density (RD, comparing treated to untreated) of TLR9 was reduced by half at one hour 
post cycloheximide treatment and this level was stable out to the eight hour time point 
(Figure 3.3A). gp96 co-immunoprecipitated with TLR9 at a consistent ratio (RD, 
comparing gp96 to TLR9) regardless of the treatment time and the cycloheximide dose 
had no effect on the expression of gp96 (Figure 3.4). These data indicated that gp96 
remained associated throughout the lifetime of the TLR9 protein.  
 
To determine whether TLR9 and gp96 traffic to the same compartment after TLR9 exits 
the ER, we performed immunoblot analysis on fractions from HEK293 cells stably 
expressing N-terminally hemaglutinin-tagged human TLR9. Organelle fractionation 
resolved early endosomes (Rab5), ER (calnexin) and lysosomes (LAMP-1) (Figure 
3.3B). Note that some Rab5 and LAMP-1 overlapped with calnexin-positive ER fractions 
but Rab5+LAMP-1- and Rab5-LAMP-1+ fractions were evident. Approximately 6-13% of 
TLR9 and 37.1% of gp96 was detected in LAMP-1+Rab5- fractions (Figure 3.3C).  
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Figure 3.3 (previous page). Lysosomal TLR9 Binds gp96. (A) HEK293 cells stably 
expressing N-terminally HA-tagged human TLR9 (HA-hTLR9) were pretreated with 10 
µg/ml cycloheximide (CHX) for the indicated times prior to cell lysis and HA 
immunoprecipitation followed by HA and gp96 immunoblotting. Relative densities (RD) 
were calculated as described in the methods and data are representative of two 
independent experiments (B) Sub-cellular fractions from HEK293 cells stably expressing 
N-terminally HA-tagged human TLR9 (HA-TLR9) were resolved by SDS-PAGE, and 
immunoblotted for early endosomes (Rab5), ER (calnexin), Lysosomes (LAMP-1), HA 
(TLR9), and gp96. (C) Densitometric analysis for (B). Each line depicts an individual 
marker and is represented as percent of total for that marker. (D) Combined LAMP-1 
positive fractions (17-21) from (C) were immunoprecipitated for TLR9 and 
immunoblotted for TLR9 and gp96 Representative of three independent experiments. 
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Figure 3.4. gp96 expression is unaffected by drug treatments.  HEK293 cells were 
pretreated with the indicated concentration of drug for either 6 hrs (CHX) or 2.5 hrs (GA 
and WS13). Whole cell lysates were immunoblotted for gp96 and tubulin. 
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These results indicate that TLR9 and gp96 both traffic out of the ER to the lysosomal 
compartment and most likely remain associated. However, given the increased 
representation of gp96 in these fractions as compared to TLR9, there are likely additional 
gp96 client proteins in the lysosomal compartment. To confirm that TLR9 and gp96 
directly interacted in the lysosomal fractions, the LAMP1+ fractions were combined and 
immunoprecipitated for either TLR9 or gp96. TLR9 was detected in both the total pooled 
fractions and following TLR9 immunoprecipitation (Figure 3.3D).  Similarly, gp96 was 
detected in the total pooled, and immunoprecipitated fractions, but was also detected in 
the TLR9 immunoprecipitate (Figure 3.3D). Therefore, gp96 associated with TLR9 in the 
endolysosomal compartment. It is important to note that we were unable to detect the 
mature form of TLR9 in these experiments due to the fact that the TLR9 in this 
experiment was N-terminally tagged and the anti-tag antibody would not detect the 
mature form as the cleavage event would remove the HA tag from the mature form. 
However, it is also relevant to note that HEK293 cells poorly proteolytically process 
TLR9 without co-expression of the ER transmembrane protein UNC93B1 (Figure 3.5). 
 
Inhibition of gp96 has no effect on TLR9 oligomerization 
Since dimerization is required for TLR9 signaling (104), we next asked if disruption of 
the gp96-TLR9 interaction disrupted TLR9 homodimer formation. When HA-hTLR9 and 
wild-type human TLR9 C-terminally tagged with YFP (hTLR9-YFP) were co-expressed 
in HeLa cells, immunoprecipitation with antibodies to GFP, which also react to YFP, 
resulted in the precipitation of both hTLR9-YFP and HA-hTLR9, indicating oligomer 
formation in the absence of ligand (Figure 3.6). 
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Figure 3.5. HEK293 cells require UNC93B1 to generate mature TLR9.  HEK293 
cells were transfected with mTLR9-HA plus empty vector or UNC93B1 and lysates were 
immunoblotted for HA. Arrows indicate full length TLR9 (FL); proteolytically cleaved 
TLR9 (PC). 
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Figure 3.6.  Inhibition of gp96 does not affect TLR9 dimer formation. HeLa cells 
transfected with combinations of human hTLR9-YFP, HA-hTLR9 and vector  were 
pretreated with 2 µM Geldanamycin (GA), 2 µM WS13 (W) or DMSO (D) for 2.5 hours. 
GFP immunoprecipitates (IP) were assayed for GFP and HA by immunoblotting. One of 
two similar experiments. 
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Pretreatment with either geldanamycin or WS13 had no effect on the ability to co-
immunoprecipitate HA-hTLR9 with hTLR9-YFP. Therefore, we conclude that gp96 does 
not regulate TLR9 oligomerization. 
 
gp96 binds CpG DNA independent of TLR9 
Our preliminary data suggest that TLR9 and gp96 are still associated outside of the ER in 
the lysosomal compartment (Figure 3.3). Furthermore, inhibition of gp96 function 
inhibited CpG DNA induced signaling events (Figure 3.1A, C, and G). Since the TLR9-
gp96 interaction is stable we next asked whether TLR9 which had bound CpG DNA still 
associated with gp96. As expected when lysates from HEK293 cells or HEK293 cells 
stably expressing hTLR9-YFP were incubated with 5 µM 3’ biotinylated CpG, TLR9 was 
only detected in affinity purifications from TLR9 expressing cells (Figure 3.7). 
Interestingly, in the non-TLR9 expressing cells, gp96 was purified with the 3’bt CpG 
DNA indicating that gp96 is capable of direct binding to CpG DNA. Previous published 
data demonstrated that commercially available purified human Hsp90 was able to bind 
CpG DNA in an electrophoretic mobility shift assay in a sequence dependent manner 
(105). Bandholtz et al. demonstrated that Hsp90 preferentially interacted with CpG DNA 
which was known to be immunostimulatory, while non-stimulatory sequences showed 
little to no binding (105). We were unable to draw any conclusions from this experiment 
as the direct binding of gp96 to 3’bt CpG DNA prevents us from addressing whether or 
not TLR9 which has bound CpG DNA is still associated with gp96. 
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Figure 3.7. gp96 binds CpG DNA independent of TLR9. HEK293 or HEK293 cells 
stably expressing hTLR9-YFP were lysed and lysates were incubated with 3’biotinylated 
CpG 2006 (5 µM ) for 1 hr at 4°C then affinity purified (AP) with streptavidin (SA) 
coated beads (SA AP). SA APs were immunoblotted for GFP and gp96.  
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Inhibition of gp96 alters TLR9 distribution  
We next asked whether altered localization of TLR9 accounted for the reduced CpG 
DNA-induced ERK phosphorylation (Figure 3.1A) and TNF-α secretion (Figure 3.1G) in 
gp96 inhibitor treated cells. HEK 293 cells stably expressing HA-hTLR9 were treated 
with vehicle control or geldanamycin. Similar to our previous observations ((55), and 
Figure 3.3B), untreated cells contained TLR9 in the ER and lysosomal fractions (Figure 
3.8A, and 3.8B and 3.8C, white bars). Following treatment with geldanamycin the level 
of TLR9 in lysosomes was reduced, but there was an increase in TLR9 in lighter density 
fractions (Figure 3.8A, 3.8B and 3.8C, black bars). This new localization might represent 
accumulation of TLR9 in the Golgi compartment, which localizes between the Rab 5 
positive early endosomes and the calnexin positive ER fractions (55), while loss of TLR9 
from the lysosomal fractions likely reflects changes in TLR9 conformation and 
proteolytic degradation as addressed below. These experiments highlight additional 
chaperoning functions of gp96 outside of chaperoning ER exit.  
 
Proteolytic processing of TLR9 requires gp96 
CpG DNA response by TLR9 depends on several events including intracellular 
trafficking to endosomes, ligand binding, conformational changes and proteolytic 
processing (52,53,80,86,104). Hsp90 family members, including the ER paralog gp96, 
regulate client protein conformations and ligand binding. To address whether TLR9 was 
proteolytically processed in the absence of functional gp96, we used a pair of mouse B 
cell lines: one wild type (WT) and one functionally deficient for gp96 (mutant, MT) (73).  
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Figure 3.8 (previous page). Inhibition of gp96 changes the localization of TLR9. (A) 
HEK293 cells stably expressing HA-hTLR9 were either left untreated or treated with 
2µM GA for 1 hour, and subcellular fractions were assayed by immunoblotting for early 
endosomes (Rab5), ER (calnexin), Lysosomes (LAMP-1), and HA (TLR9), (B) 
Immunoblots for TLR9 from (A) were subjected to densitometric analysis as in and 
graphed on the same graph. GA, geldanamycin. Data are representative of three 
independent experiments. (C) Densitometric analysis for a similar experiment as in (B) 
showing reproducibility of trend for change in localization upon treatment with GA.  
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Both cell lines contain a stably integrated NF-κB-driven green fluorescent protein (GFP) 
reporter (NF-κB-GFP). Flow cytometric analysis showed that both cell lines respond to 
phorbol myristic acid (PMA) stimulation by up-regulating GFP expression (Figure 3.9A). 
While CpG DNA stimulation induced an increase in GFP expression from the wild type 
cells, the mutant cells failed to respond (Figure 3.9A). These studies confirm previous 
findings that gp96 is required for TLR9 response (72). When these cells were retrovirally 
transduced with hemaglutinin-tagged mouse TLR9 (mTLR9-HA), less total TLR9 protein 
was immunoprecipitated from gp96 mutant cells. Furthermore, gp96 was co-
immunoprecipitated with TLR9 in the wild type cells but not in the gp96 mutant cells 
(Figure 3.9B). We hypothesized that TLR9 may fail to be properly folded and 
glycosylated in the absence of functional gp96. However, TLR9-HA showed no 
difference in sensitivity to endoglycosidase H or PNGase F regardless of gp96 status 
(Figure 3.9C). Importantly, the level of TLR9 observed in gp96 wild type and mutant 
cells was similar (Figure 3.9C). Differences in TLR9 levels observed between wild type 
and mutant cells after immunoprecipitation suggest that TLR9 is subject to post-lysis 
proteolysis (compare Figure 3.9B to Figure 3.9C). To determine whether lack of 
proteolytic processing in gp96 mutant cells was due to failure of TLR9 to exit the ER, we 
tested whether TLR9 expressed glycan modifications characteristic of Golgi processing 
(55). Datura stramonium (DS) lectin binds to hybrid and complex glycan residues, which 
only occur on proteins that have reached the Golgi compartment (55). DS lectin bound to 
mTLR9-HA from wild type, but only weakly to mTLR9-HA from gp96 mutant cells 
(Figure 3.9D).  
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Figure 3.9 (previous page). Proteolytic processing of TLR9 requires gp96. (A) Wild 
type (WT) and gp96 mutant (MT) cells were stimulated with 1 µM CpG or 50 ng/mL 
PMA for 24 hours and expression of an NF-κB driven green fluorescent protein (GFP) 
reporter was measured by flow cytometry (open histograms). Shaded histograms, 
untreated. One of three similar experiments. (B) WT and gp96 mutant (MT) cells were 
retrovirally transduced with mouse TLR9-HA (mTLR9-HA). HA immunoprecipitates 
were analyzed for HA and gp96 expression by immunoblotting. (C) RAW 264.7 cells 
were transduced with TLR9-HA and lysates were either left untreated (-) or treated with 
endoH (H) or PNGase F (F) prior to SDS-PAGE and immunoblotting for HA. (D) As in 
(B) except immunoprecipitates analyzed for HA by immunoblotting and binding of 
Datura stramonium lectin (DSL) by lectin blotting. Relative densities (RD) were 
calculated as described in the methods. (E) WT, gp96 mutant B cells and RAW 264.7 
(RAW) cells were left untransduced or transduced with TLR9-HA and analyzed for HA 
by immunoblotting. Two different exposure times (10 Seconds for RAW 264.7 and 30 
minutes for WT and gp96 mutant B cells) are shown due to the increased expression of 
both full length TLR9 and p80 in RAW 264.7 cells. IP, immunoprecipitation; FL, full 
length; PC, proteolytically processed TLR9; p80, 80 KDa form. One of three similar 
experiments. 
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Since TLR9 does not associate with mutant gp96 and only partially acquires glycans 
indicative of ER exit in cells lacking functional gp96, we next asked if TLR9 was 
proteolytically processed in gp96 mutant cells. Both full length TLR9 and three bands 
running at approximately 80 kilodalton were detected in lysates from wild type cells 
transduced with mTLR9-HA (Figure 3.9E). However, less TLR9 was expressed by the 
gp96 mutant cells and little mature TLR9 was detected; compare RD of TLR9 and 
TLR9/DSL (Figure 3.9E). Interestingly, the level of mature TLR9 in wild type mouse B 
cells (Figure 3.9E, WT) was significantly less than that present in mouse macrophages 
(Figure 3.9E, RAW, note the exposure times were different: B cells 30 minutes; 
macrophages 10 seconds). Therefore, although proteolytic processing was not as robust 
in B cells, in the absence of functional gp96, TLR9 was still proteolytically processed. 
 
Disruption of the gp96-TLR9 interaction enhances TLR9 proteolytic sensitivity 
Since TLR9 remained associated with gp96, and pharmacologic inhibition of gp96 
inhibited TLR9 signaling, we next asked whether inhibition of gp96 induced proteolysis 
of TLR9. We utilized both geldanamycin and WS13 as they inhibit gp96 through 
different mechanisms. In HEK293 cells stably expressing hTLR9-YFP pretreated with 
geldanamycin, little to no gp96 was co-immunoprecipitated with TLR9 (Figure 3.10A). 
In contrast, WS13 does not disrupt association of gp96 with client proteins (106) thus 
TLR9 and gp96 were co-immunoprecipitated even in the presence of WS13 (Figure 
3.10A). RAW 264.7 macrophages were retrovirally transduced with C-terminally HA 
tagged mouse TLR9. As expected, both full length TLR9 and the mature form were 
detected in HA immunoprecipitates.  
  58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  59 
 
 
Figure 3.10 (previous page). Inhibition of gp96 increases TLR9 sensitivity to 
proteolytic digestion. (A) HEK293 cells stably expressing human TLR9-YFP (hTLR9-
YFP) were treated with DMSO or the indicated concentrations of geldanamycin (GA) or 
WS13 for 1 hour. Cells were lysed and immunoprecipitated for GFP, or with no antibody 
(beads alone), and immunoblotted for GFP and gp96. Representative of two independent 
experiments. (B) RAW 264.7 cells were transduced with C-terminally HA-tagged mouse 
TLR9 (mTLR9-HA) and treated with 2 µM geldanamycin (GA) for the indicated times. 
HA immunoprecipitates (IP) were assayed by immunoblotting (IB) for HA. FL, full 
length TLR9; PC, proteolytically cleaved TLR9. Representative of three similar 
experiments. (C) As in (B) except cells lysed in sample buffer (wcl) were assayed by 
immunoblotting (IB) for HA and some cells were pretreated with vehicle control 
(DMSO). Representative of two similar experiments. Arrows indicate full length TLR9 
(FL); proteolytically cleaved TLR9 (PC) (D) RAW 264.7 cells were transduced with 
TLR9-HA and pretreated with either vehicle control (DMSO), 2 µM geldanamycin (GA), 
or 2 μM WS13 for 2.5 hours. Lysates were prepared as for IP and incubated at 24°C for 
the indicated times and assayed by immunoblotting (IB) for HA and tubulin. PC, 
proteolytically cleaved TLR9. Representative of two similar experiments. 
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Treatment with geldanamycin for one hour decreased the abundance of full length TLR9 
protein, yet increased an 80-kDa form, in immunoprecipitates (Figure 3.10B). Additional 
proteolytic fragments were detected after two and a half hours of geldanamycin treatment 
(Figure 3.10B, band lower than p80). Since proteolysis can occur in vitro during 
immunoprecipitation, we also examined the effect of GA and WS13 on TLR9 proteolysis 
in transduced RAW 264.7 cell whole cell lysates. In contrast to the increased proteolysis 
observed in the immunoprecipitates (Figure 3.10C), when cells were directly lysed in 
sample buffer, and the whole cell lysates were assayed by immunoblotting for TLR9, 
there was no reduction in full length TLR9, or increase in the 80-kDa form, in 
geldanamycin treated cells (Figure 3.10C). Therefore, the proteolysis we observed 
occurred during the immunoprecipitation step. We interpret these data to mean that upon 
treatment with geldanamycin, a condition where gp96 is dissociated, TLR9 has an 
increased sensitivity to proteases. This is despite the inclusion of a cocktail of broad 
protease inhibitors. Increased sensitivity to proteases could reflect a change in TLR9 
conformation. To test whether inhibition of gp96 had an effect on TLR9 proteolytic 
sensitivity, we performed an in vitro proteolysis assay. Lysates were prepared from 
mTLR9-HA retrovirally transduced RAW 264.7 cells treated with GA, where gp96 
dissociates from TLR9, and WS13, where gp96 dissociation does not occur yet gp96 
function is inhibited. Lysates were incubated at 24°C for five or 15 minutes. In lysates 
from DMSO treated cells, the abundance of a control protein, tubulin, and the abundance 
of TLR9 protein were not significantly reduced during the 15-minute incubation at 24°C 
(Figure 3.10D). In geldanamycin or WS13 treated cells tubulin levels were maintained 
while the 80-kDa form of TLR9 was dramatically reduced, even in the lysates not 
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incubated at 24°C, 0 min time point (Figure 3.10D). Interestingly, this enhancement of 
proteolysis required lysis of the cells which indicates that TLR9 does not normally come 
into contact with this particular protease in large quantities. However it is possible that 
this enhancement in TLR9 proteolysis does occur iv vivo at a reduced frequency and by 
lysing the cells we are simply enhancing the process. Therefore, we conclude that gp96 
function was required to protect TLR9 from proteolysis and potentially maintain TLR9 
conformational stability.  
 
TLR9 cleavage is not necessary for response to CpG DNA in fibroblasts 
My results up to this point demonstrate that while inhibition of gp96 induces proteolytic 
cleavage of TLR9 (Figure 3.10B and D) it in turn inhibits CpG DNA induced signaling 
events (Figure 3.1A, C, and G). These results do not support the current dogma of TLR9 
biology that states that TLR9 is obligately proteolytically cleaved prior to signaling 
(86,87). This proteolytic event occurrs between aa 741-770 and resulted in an 80 kD 
version of TLR9 reported to be the mature, and active form of the protein (86,87). This 
mature form of TLR9 is found in abundance in the phagosomes of macrophages. If 
proteolytic cleavage were required, then treatment of cells with geldanamycin, which 
induces sensitivity to proteolytic cleavage and results in cleavage to an 80 kD form of 
TLR9, similar in size to the mature form (Figure 3.10B), should enhance signaling, not 
inhibit it, as I have observed (Figure 3.1A, C, and G). Taken together, these data led me 
to question the role of proteolytic cleavage in TLR9 signaling.  
 
Previous data showed that fibroblast cell lines such as MEFs do not robustly 
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proteolytically cleave TLR9 to the mature form without the presence of UNC93B1 (86). 
However, these cells respond to CpG DNA in the apparent absence of mature 80 kD 
TLR9 (86). Co-transfection of UNC93B1 along with TLR9 into a fibroblast cell line 
causes an increase in the mature form of TLR9 (Figure 3.5) along with increased 
response to CpG DNA (86). Co-transfection with increasing concentrations of UNC93B1 
plasmid did not result in a dose dependent increase in TLR9 response to CpG DNA. 
Instead, we observed an increase in TLR9 response to CpG DNA at a 2:1 ratio of TLR9 
plasmid to UNC93B1 plasmid followed by a decrease in TLR9 response as the 
concentration of UNC93B1 plasmid increased relative to TLR9 plasmid (Figure 3.11A). 
This suggests that proteolytic cleavage is not necessary for TLR9 signaling in all cell 
types. We next asked if the proteolytic fragment is sufficient for signaling on its own. A 
C-terminally hemaglutinin (HA) tagged fragment of TLR9 encompassing residues 471-
1032 (mTLR9471-1032-HA) was readily detected when expressed in HEK293 cells (87) 
(Figure 3.11B and C).  However, this form did not reconstitute a response to CpG DNA 
in HEK293 cells (Figure 3.11D), and addition of UNC93B1 or stimulation with higher 
doses of CpG DNA did not restore response (Figure 3.12A and B). The inability of 
mTLR9471-1032-HA to respond to CpG DNA could be due to a defect in its trafficking 
outside the ER compartment and this will be discussed in a later figure. From this data we 
conclude that the mature form of TLR9 alone is insufficient to confer response to CpG 
DNA and that cleavage does not directly correlate with response to CpG DNA in 
HEK293 cells. 
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Figure 3.11 (previous page). Cleavage does not correlate with response to CpG DNA 
in HEK293 cells. (A) HEK293 cells were transfected with an NF-kB-luciferase reporter, 
TLR9 and increasing concentrations of UNC93B1 (15 ng/row, 30ng/row, or 50ng/row) as 
shown and stimulated overnight with 1 µM CpG DNA. Average luciferase activity (n=3) 
and standard deviation were determined. Representative of two independent experiments.  
(B) Model showing the proposed TLR9 cleavage site and the N-terminus of the 
mTLR9471-1032-HA construct. (C) HEK293 cells were transfected with mTLR9-HA or 
mTLR9471-1032-HA and lysates were immunoblotted for HA. Representative of two 
independent experiments. (D) HEK293 cells were transfected with an NF-kB-luciferase 
reporter, mTLR9-HA and mTLR9471-1032-HA as shown and stimulated overnight with 1 
µM CpG DNA. Average luciferase activity (n=3) and standard deviation were 
determined. Representative of three independent experiments. 
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Figure 3.12 (previous page).  Defect in mTLR9471-1032-HA signaling cannot be 
rescued by UNC93B1 or high dose CpG. (A) HEK293 cells were transfected with an 
NF-kB-luciferase reporter, mTLR9-HA and UNC93B1 or mTLR9471-1032-HA and 
increasing concentrations of UNC93B1 (15 ng/row, 30ng/row, or 50ng/row) as shown 
and stimulated overnight with 1 µM CpG DNA. Average luciferase activity (n=3) and 
standard deviation were determined. Representative of three independent experiments. 
(B) HEK293 cells were transfected with an NF-ĸB-luciferase reporter, mTLR9-HA or 
mTLR9471-1032-HA and stimulated overnight with the indicated concentrations of CpG 
DNA.  Average luciferase activity (n=3) and standard deviation were determined. 
Representative of two independent experiments. 
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Co-expression of mTLR9471-1032-HA decreases full length TLR9 signaling in 
HEK293 cells 
The Leifer lab has previously shown that a second TLR9 cleavage product, sTLR9, fails 
to signal on its own and is able to interact with full length TLR9 and inhibit full length 
TLR9 signaling (85).  To determine whether or not mTLR9471-1032-HA had a similar 
function, we next asked whether mTLR9471-1032-HA is able to oligomerize with full 
length mTLR9-GFP. TLR9 is known to exist in preformed homodimers, and dimerization 
is required for signaling (104). Co-immunoprecipitation analysis revealed that mTLR9471-
1032-HA was readily detected in immunoprecipitates of mTLR9-GFP (Figure 3.13A). 
Since mTLR9471-1032-HA was unable to respond to CpG DNA (Figure 3.11D) but was 
able to associate with full length TLR9 (Figure 3.13A) we next asked whether expression 
of mTLR9471-1032-HA could reduce signaling through the full length receptor. Indeed 
when mTLR9-HA and mTLR9471-1032-HA were co-transfected into HEK293 cells we 
observed a dose dependent decrease in mTLR9-HA response to CpG DNA (Figure 
3.13B). From this data we conclude that that mTLR9471-1032-HA reduces mTLR9-HA 
response to CpG DNA in HEK293 cells. These data are inconsistent with mature TLR9 
being that active form. The decrease in full length TLR9 response could be due to 
preferential binding of the CpG DNA to mTLR9471-1032-HA thus preventing CpG DNA 
binding to full length TLR9 dimers. This hypothesis is supported published data 
demonstrating that the mature form of TLR9 is able to bind CpG DNA (26,86,87). 
Combined with my data demonstrating that mTLR9471-1032-HA does not respond to CpG 
DNA this would indicate that mTLR9471-1032-HA is functioning as a sink for CpG DNA.  
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Figure 3.13 (previous page). mTLR9471-1032-HA reduces full length TLR9 signaling 
in HEK293 cells. (A) HEK293 cells were transfected with constructs encoding, mTLR9-
HA, mTLR9-GFP, mTLR9471-1032-HA or empty vector (pBMN-i-GFP). Cells were lysed 
and immunoprecipitated for GFP followed by GFP and HA immunoblotting. 
Representative of two independent experiments. (B) HEK293 cells were transfected with 
an NF-ĸB-luciferase reporter, mTLR9-HA and increasing concentrations (10 ng 
plasmid/row, 50 ng plasmid/row, or 100ng plasmid/row) of mTLR9471-1032-HA then 
stimulated overnight with 1 µM CpG DNA. Average luciferase activity (n=3) and 
standard deviation were determined. Representative of two independent experiments. 
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However, a second possibility is that mTLR9471-1032-HA is able to change the localization 
of full length TLR9 to an intracellular compartment which prevents the recognition of 
DNA. 
 
mTLR9471-1032-HA is not sufficient to reconstitute CpG DNA response in 
macrophages 
Since the precise location of the TLR9 cleavage event is unknown, one explanation for 
our results is that we generated a fragment that did not correspond to the mature form. 
Although we generated our fragment using the published primers used to synthesize 
mature TLR9, which reconstituted response to CpG DNA in TLR9 deficient dendritic 
cells (87), it was possible that we were lacking an important part of TLR9. Mature TLR9 
has been published to lack the entire hinge region (aa 441-470) (87).  However, this hinge 
region may play an important role in the localization of the protein since a construct of 
TLR9 lacking only this hinge region fails to co-localize with Aspergillus fumigatus 
containing phagosomes and demonstrates reduced response to CpG DNA (87,107). 
Therefore, we generated a C-terminally HA tagged protein corresponding to residues 
441-1032 of TLR9, which contained the hinge region in addition to LRR15 to the C-
terminus (mTLR9441-1032-HA) (Figure 3.14A). We next asked whether mTLR9471-1032-HA 
or mTLR9441-1032-HA reconstituted CpG DNA response in a TLR9-/- macrophage cell 
line. This line is derived from murine TLR9-/- bone marrow cells on a C57BL/6 
background immortalized with the replication deficient retrovirus J2 and was obtained 
from BEI Resources.  
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Figure 3.14 (previous page). mTLR9471-1032-HA and mTLR9441-1032-HA cannot 
reconstitute CpG DNA response in a TLR9-/- macrophage cell line due to a defect in 
ER exit. (A) Model showing the proposed TLR9 cleavage site and the N-terminus of the 
mTLR9471-1032-HA and mTLR9441-1032-HA constructs. (B) TLR9-/- macrophages were 
retrovirally transduced with empty vector, mTLR9-HA, mTLR9471-1032-HA, or 
mTLR9441-1032-HA and stimulated for 30 min with media (-) or CpG DNA (+) or LPS. 
Whole cell lysates were assayed for phosphorylated (p-p38) and total p38 by 
immunoblotting. (C) Intracellular cytokine staining for TNF-α production by TLR9-/-
 macrophage retrovirally transduced with vectors encoding mTLR9-HA or mTLR9471-
1032-HA and stimulated for 6 hr with CpG DNA (5 µM). Brefeldin A (10 µg/mL) was 
included for the final 4 hr, prior to fixing and staining with anti-HA and anti-TNF-α; 
TNF-α expression by HA+ cells is presented as mean fluorescence intensity (MFI). 
Representative of two independent experiments. (D) Lysates from TLR9-/- macrophage 
transduced with retroviral vectors encoding mTLR9-HA, mTLR9471-1032-HA, or 
mTLR9441-1032-HA were left untreated (-) or treated with endoglycosidase H (H) or 
PNGase F (F) and immunoblotted for HA. Arrows indicated endoglycosidase H treated 
samples. Representative of two independent experiments.   
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TLR9-/- macrophages were retrovirally transduced to reconstitute the cells with mTLR9-
HA, mTLR9471-1032-HA or mTLR9441-1032-HA, and stimulated with CpG DNA. At 30 
minutes post-CpG DNA stimulation, p38 was phosphorylated only in cells reconstituted 
with wild type TLR9 (Figure 3.14B). However, neither mature TLR9, mTLR9471-1032-HA, 
nor the mature form plus the hinge, mTLR9441-1032-HA, were capable of reconstituting 
signaling, despite all of the cells responding similarly to LPS stimulation due to 
endogenous TLR4 expression (Figure 3.14B). We conclude that the hinge region of 
TLR9 is insufficient to rescue the defect in CpG DNA response observed for mature 
TLR9. TLR9 is synthesized in the ER and must traffic to the endolysosomal compartment 
in order to encounter its ligand, CpG DNA (31,52,53). One potential explanation for the 
inability of mTLR9471-1032-HA and mTLR9441-1032-HA to reconstitute CpG DNA response 
is that on their own the two proteolytic fragments are unable to access endosomes, and 
thus CpG DNA. In order to test this we took advantage of the fact that naturally 
generated mature form displays a partial endoglycosidase H (endo H) resistance, 
indicating that the sugars present on the protein had been modified in  the Golgi (86,87). 
While proteins are still in the ER they are glycosylated with high mannose structures. As 
proteins traffic out of the ER these high mannose glycan structures are trimmed and 
modified in the Golgi apparatus. Naturally generated mature TLR9 displays a partially 
endo H resistance characteristic of modification in the Golgi (Figure 3.14D, left) (86,87). 
However, the glycosylations present on the mTLR9471-1032-HA and mTLR9441-1032-HA 
constructs are completely endo H sensitive (Figure 3.13D, compare arrows). The 
molecular weights of all the TLR9 fragments were reduced to the predicted sizes by 
treatment with PNGase F, an enzyme which will remove all N-linked glycans (Figure 
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3.14D). Therefore, we conclude that the reason that the mTLR9471-1032-HA and 
mTLR9441-1032-HA constructs fail to respond to CpG DNA is that they are unable to 
access the endosomal compartment.  
 
Only full length TLR9 reconstitutes CpG DNA response in TLR9-/- primary cells   
Previously published data shows that mature TLR9 reconstitutes CpG DNA signaling in 
bone marrow derived dendritic cells from TLR9-/- mice (TLR9-/- BMDC) (87). However, 
our data suggests that mTLR9471-1032-HA is insufficient to reconstitute CpG DNA 
signalling in HEK293 cells and a TLR9-/- macrophage cell line (Figure 3.11, 3.12 and 
3.14). We hypothesized that the disparity between our results could be a result of 
differences in the cell types used. While we observed that mature TLR9 did not 
reconstitute signaling in HEK293 cells or a macrophage cell line (Figure 3.11, 3.12, and 
3.14), mature TLR9 did reconstitute signaling in primary dendritic cells (87). To test this 
we generated bone marrow-derived macrophages (BMM) and bone marrow-derived 
dendritic cells (BMDC) from TLR9-/- mice. Differentiation of these cells was confirmed 
via staining with anti-F4/80 (macrophage marker) and anti-CD11c (dendritic cell 
marker). Using our protocol we were able to achieve approximately 85% cell 
differentiation into BMM and 50% differentiation into BMDC (Figure 3.15). Similar to 
the result obtained with the TLR9-/- cell line, TLR9-/- BMM retrovirally transduced with 
mTLR9-HA produced TNF-α when stimulated with CpG DNA (Figure 3.16, top panel), 
while TLR9-/- BMM  retrovirally transduced with mTLR9471-1032-HA did not (Figure 3.16, 
top panel). TLR9-/- BMM responded equally to LPS stimulation through constitutive 
expression of TLR4 regardless of transduction (Figure 3.16, top panel).  
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Figure 3.15. Differentiation of TLR9-/- bone marrow cells into macrophage or 
dendritic cells. TLR9-/- bone marrow cells were treated as described methods to 
differentiate into bone marrow derived macrophage (BMM) or bone marrow derived 
dendritic cells (BMDC). Cells were then stained with anti-F4/80 (macrophage marker, 
top) or anti-CD11c (dendritic cell marker, bottom). 
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Figure 3.16. mTLR9471-1032-HA fails to reconstitute CpG DNA induced signaling in  
TLR9-/-  primary cells. Intracellular cytokine staining for TNF-α production by TLR9-/- 
BMM (top) and BMDC (bottom) retrovirally transduced with vectors encoding mTLR9-
HA or mTLR9471-1032-HA and stimulated for 6 hr with CpG DNA (5 µM) or LPS (100 
ng/mL). Brefeldin A (10 µg/mL) was included for the final 4 hr, prior to fixing and 
staining with anti-HA and anti-TNF-α; TNF-α expression by HA+ cells is presented as 
mean fluorescence intensity (MFI). 
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Our data indicate that mature TLR9 is insufficient to reconstitute CpG DNA induced 
TNF-α production in TLR9-/- BMM. Published data only demonstrate mature TLR9 
functions in TLR9-/- BMDC (87), raising the possibility that the activity of mature TLR9 
is unique to dendritic cells.  However, this is not the case as TLR9-/- BMDC retrovirally 
transduced with mTLR9471-1032-HA failed to produce TNF-α in response to CpG DNA, 
while TLR9-/- BMDC retrovirally transduced mTLR9-HA produced TNF-α when 
stimulated with CpG DNA (Figure 3.15, bottom panel). As was the case with TLR9-/- 
BMM, TLR9-/- BMDC responded equally to LPS stimulation regardless of transduction 
through the constitutive expression of TLR4 (Figure 3.16, bottom panel). The data from 
Figure 3.16 are summarized graphically in Figure 3.17, depicting TNF-α expression as 
mean fluorescence intensity (MFI) of cells which are stained by anti-HA. From this data 
we conclude that mature TLR9, mTLR9471-1032-HA, is insufficient to reconstitute a CpG 
DNA response in primary TLR9-/- BMM or BMDC. 
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Figure 3.17. CpG DNA induced signaling is not reconstituted by mTLR9471-1032-HA. 
Graphical representation of the data from Figure 3.16 depicting the MFI of TNF-α 
staining of TLR9-/- BMM (A and B) and BMDC (C and D) retrovirally transduced with 
vectors encoding mTLR9-HA or mTLR9471-1032-HA and stimulated for 6 hr with CpG 
DNA (5 µM, A and C) or LPS (100 ng/mL, B and D). 
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CHAPTER 4: 
DISCUSSION 
 
Summary of findings 
TLRs are one of the primary mechanisms utilized by the innate immune system to 
recognize the threat of, and initiate response to, invading pathogens (108). TLR9, the 
receptor for CpG DNA, is part of a larger subfamily of TLRs responsible for recognizing 
nucleic acids (7,96,109). Regulation of nucleic acid sensing TLRs is critical as their 
ligands are not only expressed by pathogens, but additionally as self. In this thesis I 
examined two mechanisms of regulating TLR9 function: association with the heat shock 
protein gp96 (66,67,73) and activation of proteolytic cleavage (82,86-88). 
 
First I examined the role of the heat shock protein gp96 in TLR9 signaling. Published 
data established a role for gp96 in the folding and ER exit of TLR9. However, this work 
was conducted using mutant cell lines and cell specific knockouts which would mask any 
additional role for gp96 in TLR9 signaling beyond the initial protein folding events and 
subsequent exit from the ER compartment (66,72,73). I have shown that inhibition of 
gp96 function via a proprietary gp96 specific inhibitor, WS13, reduces TLR9, but not 
TLR3 or TLR4, response as detected by NF-κB reporter activation, phosphorylation of 
the MAP kinase ERK, and TNF-α secretion. The interaction between TLR9 and gp96 is 
sufficiently stable that the two proteins can be co-immunoprecipitated up to eight hours 
after inhibition of protein synthesis by cycloheximide. Preliminary results indicate that 
TLR9 and gp96 can be co-immunoprecipitated in the lysosomal compartment of HEK293 
cells, however, this result must be confirmed using alternative methods. This stable 
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association between TLR9 and gp96 most likely protects TLR9 from proteases, as 
inhibition of gp96 function by pretreatment with WS13 or the commercially available 
gp96 inhibitor geldanamycin increases the sensitivity of TLR9 to proteolysis. The 
sensitivity to proteolysis is most likely caused by a conformational change in TLR9 after 
inhibition of gp96 function that exposes sites on the TLR9 protein that are normally 
buried, as it is not observed in geldanamycin or WS13 treated cells which are directly 
lysed in sample buffer.  
 
Inhibition of gp96 function leads to induced proteolysis of TLR9 and generation of a 
fragment of TLR9 which was 80 kD in size, the same molecular weight as the proposed 
mature form (86,87). Contrary to what the literature suggests, increased 80 kD fragment 
generation did not correlate with enhanced response to CpG DNA, but rather a reduction. 
This contradiction between the published literature and my own results led me to address 
whether or not the 80 kD mature form of TLR9 is sufficient to reconstitute CpG DNA 
induced signaling. I have shown that enhancing cleavage of TLR9 in a cell line that does 
not normally cleave TLR9, HEK293 cells, via co-transfection with the ER 
transmembrane protein UNC93B1 only increases the magnitude of response to CpG 
DNA at low concentrations of UNC93B1. Furthermore, expression of mTLR9471-1032-HA 
alone was insufficient to reconstitute CpG DNA induced signaling in HEK293 cells and 
when co-expressed with mTLR9, mTLR9471-1032-HA was able to both associate with, and 
reduces the response of, full length TLR9 to CpG DNA. In cell types that normally 
generate mature TLR9, such as macrophages or DCs, mTLR9471-1032-HA alone was 
insufficient to reconstitute CpG DNA induced phosphorylation of the MAP kinase p38, 
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or TNF-α induction. The inability of mTLR9471-1032-HA to reconstitute CpG induced 
signaling correlates with an inability to traffic outside of the ER compartment as 
determined through complete sensitivity of mTLR9471-1032-HA glycosylations to endo H 
treatment.  
 
Mechanisms of GA and WS13 and their effect on TLR9 proteolysis and signaling 
The two inhibitors used in this study, geldanamycin and WS13, have different 
mechanisms of gp96 inhibition. In cells pretreated with geldanamycin, little to no gp96 
was co-immunoprecipitated with TLR9, while co-immunopreciptation between TLR9 
and gp96 was unaffected by WS13 (Figure 3.9A). Crystallographic and biochemical 
investigations suggest that geldanamycin preferentially interacts with Hsp90 in an apo, 
open-conformation, that is unfavorable for certain client protein binding (106,110-112). 
In contrast, PU-H71 and WS13 preferentially associate with an ATP-bound conformation 
of Hsp90, or for WS13, gp96, which stabilizes client protein/Hsp interaction (113). Thus, 
while recognizing similar Hsp90 species, WS13 and geldanamycin induce distinct 
conformations in Hsp90 and/or gp96 upon binding, leading to client protein trapping or 
release, respectively. Since both inhibitors block CpG DNA-induced signaling (Figure 
3.1) and increase TLR9 proteolytic sensitivity (Figure 3.10D), we conclude that the 
chaperoning activity of gp96 requires both binding to and dissociation from TLR9. 
Although I attempted to address whether or not CpG DNA associated TLR9 remains 
associated with gp96, the results were inconclusive because gp96 bound CpG DNA 
(Figure 3.7). Indeed, gp96 from non-TLR9 expressing cells was affinity purified by 
3’biotinylated CpG DNA (Figure 3.7). Previously published data using an electrophoretic 
  82 
mobility shift assay demonstrated that cytosolic Hsp90 also bound stimulatory CpG DNA 
sequences (105). Warger et al demonstrated that incubation of the gp96 N-terminus with 
concentrations of TLR2 or TLR4 ligands too low to activate dendritic cells induced both 
dendritic cell maturation and proinflammatory cytokine production (114). These data 
support my result that gp96 itself binds CpG DNA. 
 
Model for gp96 regulation of TLR9 signaling  
Our findings have uncovered a new role for the heat shock protein gp96 in the multi-step 
process of TLR9 maturation and intracellular trafficking as summarized in Figure 4.1. 
Upon exit from the ER, TLR9 transits through the Golgi apparatus and it is sorted to 
endolysosomes (52,53,55). Once in the endosomal compartment, TLR9 is proteolytically 
processed to generate an 80-kDa fragment containing about one-half of the ecto-domain, 
the transmembrane domain and the cytoplasmic tail (86,87). This form of the receptor is 
proposed to be the mature form of TLR9 that binds CpG DNA and elicits a cellular 
response. In the absence of functional gp96, TLR9 is not appropriately trafficked or 
proteolytically processed (Figure 4.1 “1”) (67,72,73). Therefore, a major function of gp96 
is to chaperone TLR9 in the ER, assisting TLR9 in folding, maturation and exit from the 
ER. The ER-resident protein CNPY3 (PRAT4A) assists gp96 in chaperoning TLRs by 
coordinating binding of gp96 to its client protein, TLR9 (67). Another chaperone, 
UNC93B1, is required for TLR9 endosomal translocation (Figure 4.1 “2”) (57). One 
potential hypothesis to explain the reduced ER exit of TLR9 in the absence of functional 
gp96 may be that gp96 is required for formation of a TLR9-UNC93B1 complex.  
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Figure 4.1. Model for TLR9 regulation by gp96. (1) Following synthesis in the ER, 
TLR9 traffics to the Golgi. In the absence of gp96 or CNPY3 (PRAT4A), TLR9 fails to 
exit the ER. (2) UNC93B1 associates with TLR9 and is required for TLR9 sorting to 
endosomes. Endosomal trafficking of TLR9 is also dependent on AP3. Once in 
endosomes, TLR9 remains associated with gp96 to maintain conformational stability. (3) 
Based on my studies I propose that in endosomes, TLR9 is protected by gp96 until TLR9 
can bind CpG DNA. Disruption of the TLR9-gp96 interaction inhibits signaling and 
increases TLR9 sensitivity to proteolytic digestion.  
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Recent data have also implicated adaptor protein 3 (AP3) in the endosomal translocation 
of TLR9; however, there is disagreement as to the exact role of AP3 in cytokine and 
interferon production. Sasai et al. demonstrated that plasmacytoid DC from AP3 deficient 
mice were unable to produce type I interferon in response to CpG DNA while IL-12 
production was normal (75). They went on to show that in the AP3 deficient mice TLR9 
failed to colocalize with lysosome-related organelles (75) This report contradicts the 
published literature which states that CpG DNA induced type I interferon production 
initiates from endosomes while proinflammatory cytokine production initiates from the 
lysosomal compartment (35). In contrast, Blasius et al showed a global defect in CpG 
DNA induced cytokine production (both proinflammatory and type I interferon) from the 
same AP3 deficient mouse strain (77). Here, we have shown that TLR9 and gp96 both 
traffic to lysosomes and that inhibition of gp96 inhibits signaling and increases sensitivity 
of TLR9 to proteolysis (Figure 3.1, Figure 3.10, and Figure 4.1 “3”).   
 
Potential mechanisms of TLR9 regulation via gp96 
There are several potential mechanisms by which gp96 may regulate TLR9. The ecto-
domain of TLR9 forms a solenoid of two sets of leucine rich repeats separated by an 
unordered hinge, and proteolytic processing in endosomes at the hinge generates two 
fragments, the mature form and the remaining N-terminus (N-ter). Co-
immunoprecipitation analysis has revealed that these two cleavage fragments remain 
associated (87). Therefore one possibility is that gp96 may bridge the mature form and N-
ter fragments following proteolytic cleavage. Although the mature form of TLR9 has 
been proposed to signal in response to phosphorothioate modified synthetic CpG DNAs, 
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the N-ter also contains ligand-binding domains (115), and may contribute to CG 
dinucleotide specificity. Therefore, gp96 may be required to bring the different DNA 
binding domains in close proximity to allow for appropriate ligand binding that could 
facilitate either qualitative or quantitative modification of the response (discussed in 
greater detail below). A second possibility is that gp96 may associate with TLR9 that 
failed to successfully mature and is destined for degradation in lysosomes. However, if 
gp96 targeted TLR9 to the lysosome for degradation, one would predict that dissociation 
should prevent proteolysis, not enhance proteolysis as we detected (Figure 3.10B). 
 
The most likely mechanism by which gp96 regulates TLR9 is that gp96 maintains 
conformational stability of the TLR9 ecto-domain. We showed that treatment of cells 
with geldanamycin and WS13 increased TLR9 sensitivity to proteolytic processing 
(Figure 3.10D). In our hands we observe much more mature TLR9 in macrophage lysates 
than full length TLR9, making detection of the full length protein variable and 
problematic (Figure 3.10D). However, using our assay we were able to observe a 
reproducible effect on the proteolysis of the mature form of TLR9 once gp96 was 
inhibited. Inhibition of gp96 increases the sensitivity of TLR9 to proteolysis (Figures 
3.10B and 3.10D).  
 
Previous studies demonstrated that TLR9 undergoes a major conformational change upon 
ligand binding (104). Using a TLR-Fc fusion protein, Latz et al published that the fusion 
protein alone demonstrated a circular dichroism (CD) spectrum indicative of a well 
folded protein (104). When CpG DNA was combined with the fusion protein, they 
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observed a shift in the CD spectrum consistent with a ligand induced conformational 
change (104). Latz et al. supported this study using FLIM-FRET analysis. FRET 
measures radiation-free energy transfer from an excited donor fluorophore to an acceptor 
fluorophore. Fluorescence lifetime imaging microscopy (FLIM), on the other hand, 
measures the amount of time required for an excited fluorophore to decay. Using the 
FLIM-FRET technique, Latz et al. demonstrated that there is a distance of 7.3 nm 
between the N and C terminus of TLR9, and the addition of CpG DNA reduced the 
distance by 12%, indicative of a large conformational change in the protein (104). 
Finally, they utilized a split GFP system consisting of fusing each half of a GFP 
monomer to TLR9 and then expressing both in the same cell. The two GFP fragments are 
not fluorescent unless brought into close proximity. Only when CpG DNA was added 
was GFP fluorescence detected indicating that CpG DNA induced a conformational 
change in TLR9 (104).  
 
Our data are consistent with gp96 playing a similar role for TLR9 to that of cytoplasmic 
Hsp90 and its most well studied client proteins, steroid receptors (SR). In this model the 
TLR9 polypeptide chain would associate with CNPY3 much the same way that the 
cytosolic SRs first associate with Hsp40, then Hsp70 (116). CNPY3 would assist in the 
loading of the TLR9 polypeptide chain onto gp96, which will facilitate folding of TLR9. 
After folding, gp96 would remain associated with TLR9, maintaining TLR9 in a ligand-
accessible conformation (97,99). Interestingly, in the case of Hsp90, a protein called p23 
associates with the Hsp90-SR complex and blocks Hsp90 in a substrate-binding 
conformation reinforcing stable association with its SR client (97,117,118). Perhaps 
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CNPY3 plays a similar role for gp96 in addition to facilitating gp96 binding to its 
substrates. Alternatively, there may be yet another unidentified protein in the TLR9 
complex which will fill this role. Without gp96 function, TLR9 likely unfolds, increasing 
its sensitivity to proteases, and reducing its ability to bind CpG DNA. This hypothesis 
will discussed in greater detail below.   
 
Treatment with geldanamycin increases the sensitivity of TLR9 to proteolytic 
degradation, not proteolytic degradation itself, similar to what is observed for the 
glucocorticoid and progesterone receptors (119,120). We believe that gp96 is regulating 
TLR9 function by maintaining its conformational stability and protecting TLR9 from 
premature proteolytic degradation in the endolysosomal compartment (Figure 4.1 “3”). 
Premature proteolytic degradation of TLR9 could result in two major outcomes. The first 
possibility is that the premature proteolytic degradation could result in the mature form of 
TLR9 being present in an intracellular compartment where it is colocalized with, and can 
respond to, self-DNA. This is similar to what is observed with the TLR9-4 chimera, 
which mislocalizes to the cell surface where it detects self-DNA (54). The second 
possibility is that the premature proteolytic cleavage of TLR9 results in a rapid 
degradation of TLR9, so that it cannot bind and respond to microbial or self DNA. This 
would be analagous to the inhibition observed on glucocorticoid or progesterone receptor 
signaling when cells are treated with geldanamycin (119,120). It is important to note that 
gp96 itself is destabilized at pH<5 (121), which would be encountered in lysosomes. This 
suggests that gp96 would maintain ligand-binding conformation in most endosomes, but 
when the gp96-TLR9 complex traffics to late endosomes, gp96 will dissociate and TLR9 
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will be degraded. This is likely a mechanism for TLR9 turnover to maintain low 
abundance of TLR9 in this compartment.  
 
TLR9-gp96 interaction outside of the ER 
Previous studies supported a role for gp96 in ensuring proper folding of TLR9 and exit 
from the ER compartment. This conclusion was based on the observations that, in the 
absence of functional gp96, TLRs 1, 2, and 4 were not detected on the cell surface, and 
there was no generation of mature TLR9 (66,67,72,73). If these were the only roles that 
gp96 played in TLR9 signaling, one would envision a relatively short term interaction 
between the two proteins. However, my data demonstrates a stable association between 
TLR9 and gp96. Combined with my data demonstrating that inhibition of gp96 function 
induces proteolytic cleavage of TLR9, yet inhibits signaling, I propose that gp96 has 
additional functions in TLR9 biology once TLR9 has exited the ER. Perhaps TLR9 still 
exits the ER in the absence of gp96, but once it enters the endosomal compartment, it is 
rapidly turned over due to an increased sensitivity to proteases. This hypothesis is 
supported by my data using the gp96 MT B cells which show that although reduced when 
compared to WT, a very small amount of mature TLR9 is still generated in the MT cells 
(Figure 3.9E). In addition, DSL binds to a small portion of full length TLR9 from the 
gp96 MT cells indicating that TLR9 is glycosylated in the Golgi (Figure 3.9D). These 
data suggest that TLR9 exits the ER in the absence of functional gp96, albeit to a much 
lesser extent. Although the concept of stable association of gp96 with its client proteins 
would be novel, it fits well when compared to cytoplasmic Hsp90. Although its 
chaperone functions are substrate specific Hsp90 is thought to remain associated with its 
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client proteins to perform two major functions; either protecting its client proteins from 
proteosome mediated degradation, or maintaining them in a conformation that is 
conducive to ligand binding (discussed in greater detail below) (97-99,122).  
 
Role of proteolysis in TLR9 signaling 
In contrast to the current model where the 80 kD fragment of  TLR9 is the mature and 
active form of the protein (82,86-88), my data suggest that the 80 kD fragment of TLR9 
is insufficient in any cell type, and certainly not necessary in others, to reconstitute CpG 
DNA induced signaling. This is supported by several published studies, as mentioned 
below (Table 4.1). Despite the ability to respond robustly to CpG DNA in a TLR9 
dependent manner, HEK293 cells fail to proteolytically process TLR9 to the mature form 
(55,80,85,86). More compelling perhaps, is the fact that, in B cells, very little proteolytic 
cleavage of TLR9 occurs, yet these cells respond to CpG DNA (Figure 3.5 and 3.10). 
Furthermore, even among the cell types that have been published to robustly cleave 
TLR9 there seem to be multiple cleavage events. Generation of the mature form of TLR9 
was initially observed in macrophage phagosomes and depended on cathepsins 
(82,86,87). However, in dendritc cells, the processing of TLR9 relies on AEP and 
generates additional cleavage products (88). A chimeric receptor consisting of the 
ectodomain of TLR9 and the transmembrane domain of cytoplasmic tail of TLR4 
localizes to the plasma membrane and responds to CpG DNA, but it is not proteolytically 
cleaved (54). Yet, the same group showed that TLR9 fused to a yeast ist2 sequence 
localized to the plasma membrane, was not cleaved, but now failed to respond to CpG 
DNA (86).  
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Table 4.1 Summary of published data demonstrating that proteolytic cleavage of 
TLR9 does not correlate with signaling 
 
Construct Proteolytic 
Cleavage 
Signaling Reference 
 
TLR9 
 
Yes 
 
Yes 
(86,87) 
 
TLR9 + Bafilomycin 
 
No 
 
No 
(86) 
 
TLR9-4 
 
No 
 
Yes 
(54) 
 
TLR9-ist2 
 
No 
 
No 
(86) 
 
TLR9 (B cells) 
 
No 
 
Yes 
Figure 3.9E 
 
TLR9 (HEK293) 
 
No 
 
Yes 
(55,80,85) 
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Therefore, mislocalization and cleavage does not directly correlate with signaling.  
Finally, neutralization of endosomal acidification inhibits both proteolytic cleavage in 
macrophage and response to CpG DNA in macrophage and HEK293 cells (30,31,35,87). 
In 2004 Rutz et al. utilized recombinant fusion proteins consisting of the ectodomain of 
murine TLR9 and the Fc portion of human IgG1 (mTLR9ect) in surface plasmon 
resonance biosensor-based assays to examine the binding between TLR9 and CpG (81). 
Data from Rutz et al. demonstrated that inhibitors of endosomal acidification such as 
chloroquine, quinacrine, and bafilomycin A1 inhibit CpG DNA binding to TLR9 (81).  
 
In my hands mTLR9471-1032-HA is insufficient to reconstitute CpG DNA induced 
signaling in TLR9-/- BMDC (Figure 3.15), this is in contrast to published studies (87). 
This is despite using published primers to generate the mTLR9471-1032-HA construct and 
verifying it by sequencing. The experiment was performed the same as previously 
published with the exception of using a longer stimulation time. Thus I was unable to 
confirm the only published example of mTLR9471-1032 activity. However, this does not 
eliminate the possibility that while the mature form of TLR9 may not be sufficient for 
CpG DNA induced signaling, it may be required. The fact that not all cell types 
proteolytically cleave TLR9 could merely suggest that mechanisms of regulating TLR9 
are not universal among all cell types. This view is supported by the observation that 
different cell types will produce different cytokines when stimulated with CpG DNA. For 
example, human pDCs predominantly produce type I interferon when stimulated with 
CpG DNA while macrophages predominantly produce proinflammatory cytokines 
(17,36). Data presented in this thesis demonstrate that mature TLR9 is insufficient to 
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reconstitute CpG DNA induced responses, most likely due to an inability to traffic out of 
the ER compartment (Figure 3.14). If mature TLR9 is in fact necessary in some cell types 
my data would suggest that there is an unidentified role for the N-ter in TLR9 biology 
(explored further below).  
 
Redefining the model of TLR9 trafficking and signaling  
The current dogma for the initiation of TLR9 signaling is that the protein is initially 
folded in the ER in a manner dependent on the co-chaperones gp96 and 
PRAT4A(CNPY3) (52,53,60,67,72). TLR9 exits the ER via an association with the 
transmembrane protein UNC93B1 and traffics through the Golgi apparatus to the 
endolysosomal compartment (55-57,83). Once TLR9 reaches endosomes it is 
proteolytically processed to a mature and active 80 kD form (82,86-88).  
 
My thesis challenges this model in two ways. First I propose that gp96 has additional 
functions in TLR9 biology, other than facilitating its folding in the ER. My data using 
cycloheximide reveals that the TLR9-gp96 interaction is stable, not transient (Figure 
3.3A). Using organelle fractionation I have preliminary results showing that both full 
length TLR9 and gp96 are associated in the lysosomal compartment (Figure 3.3B and C). 
The Leifer lab previously showed that TLR9 and the TLR signaling adaptor MyD88 are 
constitutively associated in the lysosome, indicating that this is the pool of TLR9 which 
is responding to CpG DNA (55). I have also shown that inhibition of gp96 function 
inhibits TLR9 signaling and increases its sensitivity to proteolytic degradation (Figure 
3.5C). Taken together, these data show that gp96 is not just a chaperone responsible for 
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folding TLR9 in the ER compartment, but that, much like Hsp90, gp96 remains 
associated with TLR9 and both protecting its client from proteolytic degradation as well 
as stabilizing it in a ligand binding conformation. The TLR9-gp96 interaction most likely 
persists to the lysosomal compartment (Figure 3.3B and C) where the CpG DNA induced 
proinflammatory cytokine production initiates (35). However, if no CpG DNA is present 
to bind to and stabilize TLR9 the low pH of the lysosomal compartment (pH<5) will 
cause destabilization of gp96 (121) resulting in dissociation from TLR9 and subsequent 
proteolytic degradation of TLR9. This could be a mechanism to regulate the amount of 
TLR9 available for CpG DNA binding in the endolysosomal compartment.   
 
The second major area challenged by this thesis is the role of proteolysis in TLR9 
signaling. As stated previously, the data present in the literature do not universally 
support the concept of obligate proteolytic cleavage to activate TLR9 (Table 4.1). My 
own data demonstrate that mTLR9471-1032-HA alone is insufficient to reconstitute CpG 
DNA induced signaling in fibroblasts, macrophages, or dendritic cells (Figure 3.11, 3.14, 
and 3.15), contradicting the only published report of mTLR9471-1032 function available in 
the literature (87). My data also show that, on its own, mTLR9471-1032-HA fails to exit the 
ER, and the addition of the TLR9 hinge region fails to rescue mature TLR9 signaling or 
ER exit (Figure 3.9 B and D). Indeed, when co-expressed with mTLR9-GFP, mTLR9471-
1032-HA is able to associate with, and reduce the signaling of, mTLR9-HA most likely by 
preventing it from exiting the ER compartment (Figure 3.8).  
 
In summary, I propose a new model in which interaction between TLR9 and gp96 is both 
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necessary in the ER to ensure maturation and after ER exit to maintain conformational 
stability. In the absence of gp96, TLR9 fails to exit the ER or is rapidly degraded once it 
moves beyond the ER compartment. The TLR9-gp96 interaction is stable over the half-
life of TLR9 and both proteins are associated in the lysosomal compartment. Inhibition of 
gp96 function changes the conformation of TLR9 and enhances sensitivity to proteolysis. 
Despite generating an 80 kD fragment analogous in size to the mature form, this 
proteolytic cleavage inhibits signaling. Proteolytic cleavage is not required in all cell 
types to facilitate CpG DNA induced signaling and the mature form of TLR9 alone is 
insufficient to reconstitute a response to CpG DNA. However proteolytic cleavage of 
TLR9 may be required in a smaller subset of cell types, such as macrophages and 
dendritic cells. It is difficult to conclude this because the inhibitors used to block 
cleavage and TLR9 signaling also directly block TLR9 binding to CpG DNA (81,82,86). 
Regardless of the requirement for proteolytic cleavage in TLR9 signaling, I speculate that 
the TLR9 N-ter plays an important but unidentified role in TLR9 trafficking or 
coordinating accessory protein binding.  
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CHAPTER 5: 
FUTURE DIRECTIONS 
 
Role of TLR9-gp96 interaction outside the ER 
My preliminary results indicate that TLR9 and gp96 are associated in the lysosomal 
compartment of HEK293 cells (Figure 3.3). While the data are promising, further 
experiments should be performed to strengthen the co-immunoprecipitation data (Figure 
3.3D). One approach would be to perform confocal microscopy on TLR9-/- macrophages 
retrovirally transduced with full length TLR9. These reconstituted macrophages could be 
immunostained for TLR9, gp96 and markers for the endosomal or lysosomal 
compartment (Rab 5 and LAMP-1, respectively), and Pearson’s coefficients could be 
calculated to determine the extent of TLR9-gp96 colocalization in both endosomes and 
lysosomes. This approach would both add support to the co-immunoprecipitation data but 
also reproduce the finding in macrophages, which will normally express TLR9. 
 
A second area for future study is the role that gp96 association plays in TLR9 biology 
outside of the ER compartment. Based upon the data presented in this study, that 
inhibition of gp96 function inhibits CpG DNA induced TLR9 responses and increases 
TLR9 sensitivity to proteolysis, I would predict that the function of gp96 is to protect 
TLR9 from proteolytic degradation and assist TLR9 in binding CpG DNA (Figure 3.1 
and 3.10) Organelle fractionation of either gp96 mutant cells or cell specific gp96 
knockouts would be useful in confirming the presence of TLR9 outside the ER in the 
absence of gp96. Similarly it would be interesting to address whether or not gp96 
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dissociation from TLR9 is required for cleavage to occur. My data on dissociation of 
gp96 and enhanced proteolysis of TLR9 would argue for this point. One method to 
address this question would be to first feed or “pulse” cells with 35S-methionine to label 
all newly synthesized TLR9. The pulsed cells could then be treated with cycloheximide 
to stop any further protein synthesis, then at fixed time points post cycloheximide 
treatment, organelle fractionation could be preformed and lysosomes isolated. These 
lysosomes could be lysed and immunoprecipitated for TLR9 and examined by auto-
radiograph for TLR9 and immunoblotting for gp96. The 35S-methionine pulse labeling 
would allow for the monitoring, or “chasing” of one pool of TLR9 as it traffics out of the 
ER to the endolysosomal compartment. In addition, immunoprecipitation from LAMP1 
positive fractions would explore the TLR9-gp96 interaction specifically in the 
endolysosomal compartment where proteolytic cleavage occurs (82,86-88). My data 
demonstrates that inhibiting gp96 function with WS13, which reinforces gp96-client 
protein interactions, still enhances sensitivity of TLR9 to proteolysis (Figure 3.10D). 
However, from this experiment, we can not observe the effect on full length TLR9. 
Additional data presented in this study suggest that full length TLR9 may be stabilized 
when cells are treated with WS13, which would suggest that dissociation of gp96 is 
required for generation of mature TLR9 (Figure 3.10A, compare WS13 treated to GA 
treated). In the context of the pulse-chase experiment outlined above I would predict that 
the TLR9, which had been proteolytically cleaved, would not be associated with gp96. 
Although I attempted to address whether or not TLR9 that had bound CpG DNA was still 
bound to gp96, no conclusions could be drawn due to the fact that gp96 was able to bind 
CpG DNA in the absence of TLR9 (Figure 3.7). Another approach would be to attempt to 
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purify TLR9 from gp96 MT B cells using 3’biotinylated CpG DNA. This experiment 
would directly address whether or not TLR9 is able to bind to CpG DNA in the absence 
of gp96.  
 
Using gp96 inhibitors as therapeutics 
Hsps have a long history as therapeutic targets for the treatment of diseases, most notably  
Hsp90 in cancer (123-128). Hsp inhibitors also demonstrate therapeutic promise through 
their immunosuppressive effects. For example, Hsp90 inhibitors halt disease progression 
in models of rheumatoid arthritis (129,130). However, targeting Hsp90 remains 
challenging, as many client proteins depend on its chaperoning function. Thus, inhibition 
of Hsp90 function may have far reaching effects on many normal cellular processes and 
be highly toxic with many adverse side effects. For example, inhibition of Hsp90 via 
geldanamycin results in suppressed ERK, glucocorticoid receptor, and progesterone 
receptor signaling (100,119,120) Furthermore, in the case of geldanamycin and its 
derivatives, the drugs themselves display dose-limiting liver toxicity (131). gp96, on the 
other hand, has a much smaller repertoire of known client proteins, making it a more 
attractive therapeutic target.  
 
gp96 may be immunologically active when detected extracellularly. A transgenic mouse 
with constitutive expression of gp96 at the cell surface via a cytomegalovirus promoter-
driven construct (96tm-Tg) developed systemic lupus erythematosus (SLE) like disease at 
>20 weeks of age (132). This SLE-like disease was characterized by both IgA and IgG 
immune complex deposition in the glomeruli of the kidney resulting in 
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glomerulonephritis and enhanced DC activation (132). Disease was also dependent on the 
TLR signaling adaptor MyD88 as lethally irradiated 96tm-Tg mice reconstituted with 
MyD88-/- bone marrow failed to develop any SLE-like disease (132). These data suggest 
that gp96 itself can be recognized as a “danger signal” by the immune system when 
detected outside of the cell and this recognition occurs via a TLR. Published data also 
show an increased expression of gp96 in the synovial fluid of human patients with 
rheumatoid arthritis (133). Previous data have also shown that inhibition of TLR9 
signaling protected mice from both autoimmune arthritis and autoimmune 
encephalomyelitis (134). These results, taken together with my data demonstrating that 
specific inhibition of gp96 inhibits TLR9 signaling, lend support to the idea of using the 
gp96 specific inhibitor WS13 as a means to control autoimmune diseases in which TLR9 
plays a role, such as SLE. While the exact role that TLR9 plays in SLE remains unclear, 
TLR9 deficient mice have reduced anti-DNA antibodies, but enhanced disease (91). A 
specific role for TLR9 in B cell responses to DNA containing immune complexes was 
supported by studies using a mouse expressing a transgenic “rheumatoid factor” receptor 
(explored in further detail below). In vitro stimulation with immune complexes that 
included DNA, such as anti-nucleosome complexes, induced proliferation of the 
transgenic B cells while non-nucleic acid complexes, such as BSA-anti-BSA complexes, 
did not. The response was DNase sensitive and dependent on MyD88 and uptake of the 
immune complexes into the endosomal compartment (34).  
 
Since constant suppression of TLR function would be detrimental to the host in terms of 
general immune function and pathogen recognition it would not be ideal to administer 
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gp96-specific inhibitors daily. However, one could imagine a treatment regimen in which 
gp96-specific inhibitors are only administered during disease reactivation to manage 
symptoms. It would be beneficial to test WS13 as a therapeutic in a mouse model of 
autoimmune disease such as the AM14 transgenic mice. The B cells of AM14 transgenic 
mice constitutively express an immunoglobulin heavy chain which when combined with 
the Vκ8 light chain yields a B cell receptor specific for mouse IgG2a antibodies, also 
called rheumatoid factor (RF) (135). This mouse model of SLE is more comparable to the 
human disease since these RF positive B cells only constitute a small portion of the total 
circulating B cell population (135-137). The main advantage of the AM14 transgenic 
model is that it allows for controlled administration of the autoantigen-immune 
complexes, for example, IgG2a antibody in complex with DNA to induce disease. The 
AM14 model allows for induction of autoimmune disease in the presence or absence of 
WS13, different time courses and dosages could also be explored. Since WS13 treatment 
inhibits TLR9 signaling, and TLR9 signaling plays a role in SLE disease progression, I 
would hypothesize that treatment with WS13 would result in a less severe disease. 
However, the role that TLR9 plays in SLE is unclear with the published literature 
demonstrating a more dominant role being played by TLR7 (91,138). Although given that 
TLR7 and TLR9 are structurally very similar and seem to share common regulatory 
mechanisms, like proteolytic cleavage and the requirement for UNC93B1, perhaps WS13 
will also inhibit TLR7 dependent responses (9,56,57,82,83,86). This question could be 
addressed by pretreating RAW 264.7 macrophages with WS13 or DMSO control and the 
stimulating with the TLR7 ligand loxoribine. Supernatants from the stimulated cells 
could then be collected and assayed for the presence of the cytokine TNF-α by ELISA. 
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Alternatively, after the WS13 or DMSO treated cells are stimulated with loxoribine, 
brefeldin A could be added to prevent secretion of cytokines. The brefeldin A treated 
cells could be fixed, permeabilized and immunostained with antibodies to TNF-α to be 
assayed by flow cytometery.  
 
A second caveat to using WS13 as a therapeutic is the possibility of infection. Even 
though other TLRs will be localized to the correct compartments to respond to ligand and 
thus won’t need gp96 function any longer, treatment with WS13 will inhibit the newly 
synthesized TLRs from trafficking to the correct compartment. This inhibition will 
eventually result in global signaling defects through most TLRs, and the opportunity for 
invasion by pathogens. Nevertheless, using WS13 to manage symptoms in autoimmune 
diseases such as SLE is just one potential regimen for using gp96 specific inhibitors as 
immunotherapeutics. 
 
The role of the N-terminal portion of TLR9  
My data indicate that there is a yet unidentified role for the TLR9 N-ter that is removed 
when the mature form of TLR9 is generated (Figure 1.3). Inspection of the TLR9 N-ter  
sequence reveals that there are potential DNA binding domains present in this portion of 
TLR9 which is removed when the mature form of TLR9 is generated (115). Since the 
TLR9 N-ter can be detected, via co-immunoprecipitation, in association with the mature 
form of TLR9, the N-ter could modify the response of mature TLR9, either qualitatively 
or quantitatively (87) The synthetic CpG DNA utilized by most researchers is 
phophorothioate modified because this form of DNA more stable in vitro and in vivo  
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(139). However, naturally occurring CpG DNA bears a phosphodiester modification (17). 
Current studies have examined the role of the mature form of TLR9 in response only to 
synthetic, phosphorothioate modified CpG DNA, not the more physiologically relevant 
phosphodiester modified CpG DNA (87,140-142). This is an important caveat because it 
the sequence specificity of the CpG hexamer motif (GACGTT for mouse and GTCGTT 
for human) is lost when the DNA backbone is phosphorothioate modified (22,81,139).  
 
Stimulatory CpG DNAs can be grouped into three main categories based on the type of 
response they induce. The first, class A, is characterized by induction of type I interferon 
production while class B CpG DNA induces B cell maturation and proinflammatory 
cytokine production (22). The third class, class C CpG DNA, displays properties of both 
class A and class B (28). More recently, a fourth class of stimulatory CpG DNA has been 
described. This class, called class P CpG DNA, functions similarly to class C CpG DNA 
in that it is able to induce both type I interferon and proinflammatory cytokine 
production. However, through the addition of a second pallindromic CpG sequence, P 
class CpG DNA induce higher type I interferon, as well as proinflammatory cytokine, 
production at a lower concentration than C class CpG DNA (143). Published studies on 
mature TLR9 function have only been conducted using class B CpG DNA and assaying 
for proinflammatory cytokine production, not class A CpG DNA and induction of type I 
interferons. I propose to reconstitute TLR9 deficient cells with either full length TLR9 or 
mature TLR9, both with and without the hinge, and  assay these cells for their ability to 
respond to different classes of CpG DNA (A, B, C, or P) and different backbone 
compositions (phosphodiester or phosphorthioate).   
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It would also be informative to use the mTLR9471-1032-HA and mTLR9441-1032-HA 
constructs that I have generated and attempt to restore response to CpG DNA by 
providing the TLR9 N-ter. This could be done either in cis, in the same vector via and 
internal ribosomal entry site, or in trans, on two separate vectors (Figure 4.2). I expect 
that providing the N-ter in cis or trans, on two separate plasmids, will reconstitute 
function in both mTLR9471-1032-HA and mTLR9441-1032-HA constructs. On their own both 
mTLR9471-1032-HA and mTLR9441-1032-HA remain sensitive to endoglycosidase H which I 
interpret to mean that the two constructs fail to exit the ER compartment. I hypothesize 
that the TLR9 N-ter is essential for ER exit. Since the N-ter retains the ability to associate 
with mature TLR9 post cleavage when the two products are expressed in the same cell 
they should be able to associate, traffic out of the ER, and respond to ligand (87). In 
addition I expect that the N-ter will modify the response to CpG DNA by defining 
specificity to both the various physical and chemical structures of DNA and the different 
classes of CpG DNA. Using retroviral transduction to perform these experiments in 
different cell types will also address the requirement for proteolytic cleavage in different 
cell types. The main caveat to this study is the assumption that the two constructs of 
TLR9, mTLR9471-1032-HA and mTLR9441-1032-HA, will be able to associate with the 
TLR9 N-ter. Published data demonstrates that mature TLR9 and the TLR9 N-ter 
associate by co-immunoprecipitation analysis. (87).  
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Figure 5.1. System for determining the role of N-ter in TLR9 signaling. TLR9-/- cells 
(macrophages and dendritic cells) will be retrovirally transduced with plasmids encoding 
full length (FL) TLR9, mature TLR9 (mTLR9471-1032), mature TLR9 + N-ter on the same 
vector via an internal ribosome entry site (IRES), or on separate vectors. Retrovirally 
transduced cells can then be assayed for the ability to respond to CpG DNA of different 
class (A, B, or C) and chemistry (phosphorothioate and phosphodiester). 
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However, this is when the two fragments are generated from full length TLR9 in a 
macrophage, so we do not know if the two fragments will associate when expressed 
independently from a retroviral vector. Co-immunoprecipitation analysis of the retroviral 
constructs will confirm that mTLR9471-1032-HA and mTLR9441-1032-HA associate with 
TLR9 N-term.  
 
Another possibility is that the N-ter coordinates binding of a chaperone essential for exit 
from the ER. Our data suggest that mTLR9471-1032-HA fails to acquire endogycosidase H 
resistance, an indicator of trafficking through the Golgi (Figure 3.9D). I interpret this to 
mean that the mTLR9471-1032-HA construct does not exit from ER compartment. Previous 
studies have shown that in the absence of two ER resident chaperones, gp96 and CNPY3, 
TLR9 fails to exit the ER compartment. Therefore, failure to associate with either protein 
is an attractive hypothesis to explain the inability of the mTLR9471-1032-HA construct to 
exit the ER (67,72). A third ER resident protein, UNC93B1, has previously been shown 
to be critical for TLR9 exit from the ER, and its localization to, and cleavage in, 
endosomes (57,83,86). However, unlike gp96 and CNPY3, UNC93B1 is a 
transmembrane protein and interacts with TLR9 via its transmembrane domain (83). The 
proteolytic cleavage event in TLR9 that generates the mature form occurs in the 
ectodomain, leaving the transmembrane domain of the protein intact and unaltered 
(86,87). Since the transmembrane domain is unaltered there should be no deficiency in 
association of mTLR9471-1032-HA with UNC93B1 making this an unlikely explanation for 
the inability of mTLR9471-1032-HA to exit the ER. However, the TLR9 N-ter could be 
important for coordinating binding of UNC93B1 directly, or through an additional 
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protein that in turn allows UNC93B1 to bind to TLR9. Published data demonstrate that  
TLR9 lacking only the hinge region, fails to colocalize with Aspergillus fumigatus 
containing phagosomes, and has a reduced response to CpG DNA (87,107). These data 
support the hypothesis that the hinge region (aa 441-470) is itself important for proper 
intracellular trafficking of TLR9. Co-immunoprecipitations from TLR9-/- macrophages 
retrovirally transduced with either full length TLR9 or mature TLR9 would determine 
whether or not mature TLR9 retains the ability to bind to gp96, PRAT4A and UNC93B1. 
These experiments would address whether the TLR9 N-ter is necessary for binding to 
accessory proteins, and would illuminate the role that the TLR9 N-ter plays in TLR9 
biology. 
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